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Mild thiamin deficiency is prevalent in diabetes, and high dose thiamin ameliorates 
some diabetic complications, but there are no definitive studies addressing thiamin 
intake, diabetes control and thiamin status in diabetes.  
Subjects were 113 people with diabetes (58 type 1, 55 type 2), 43 with and 70 
without  thiamin supplementation.  
Dietary thiamin was estimated by 24-hour recall, diabetes control by HbA1c. Age, 
BMI, albumin excretion, activity level and smoking status did not correlate with red 
cell thiamin (RCT) in either group. RCT correlated with serum thiamin (ST) (p < 
0.01). 
In those unsupplemented, adequate dietary thiamin did not ensure normal RCT, with 
15.7 % of subjects below the reference range. Supplementation to intake > 4 mg/d, 
was significantly associated with normal RCT (p = 0.028), with 97.7% of 
supplemented subjects having normal RCT. Supplementation was also significantly 
associated with elevated serum thiamin 24 hours post supplementation, contrary to 
other reports. HbA1c was not significantly associated with RCT.   
Conclusions: In diabetes, adequate dietary thiamin does not ensure normal red cell 
thiamin, but supplementation to > 4 mg/day does, raising questions about actual 
thiamin requirements in diabetes and supporting evidence that thiamin deficiency in 
diabetes is not primarily due to dietary deficiency. Diabetes control was not 
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CHAPTER 1        INTRODUCTION 
                                                    
1.1  Statement of the problem 
 
Thiamin is present in a variety of foods, especially cereals. BMI, age, activity and 
smoking status can be modifiers of blood thiamin levels but in the absence of 
excessive alcohol, a low blood thiamin level is normally a marker of inadequate 
dietary intake.1 There are a number of reports citing a greater incidence of 
suboptimal blood thiamin levels in those with diabetes compared to those without,2-4 
and also reports that conflict with this.5 A study on food intake in 50 people with 
type 2 diabetes showed that dietary intake of thiamin was well above the RDI in 98% 
of subjects6 and there is evidence that thiamin intake in type 1 diabetes is also 
adequate.7 However there is some evidence of increased excretion of thiamin in those 
with diabetes when compared to those without.2  Human, animal and in vitro studies 
have shown that high dose supplementation by thiamin and its derivatives ameliorate 
complications of diabetes.8 This suggests that low thiamin blood levels may be 
related to the diabetic state rather than to inadequate dietary intake. Although a 
recent researcher has stated that decreased plasma thiamine concentration in clinical 
diabetes was probably not due to a deficiency of dietary input of thiamine,2 this has 
not been demonstrated, and there are no definitive studies addressing dietary intake 
and thiamin status in diabetes. Unless this area is researched, it cannot be definitively 
stated how thiamin deficiency in diabetes is related to  dietary intake, if indeed it is 
related at all. In addition, it has not been established that thiamin status in diabetes is 
not inappropriately diminished by other known modifiers, or by poor control of 
diabetes.  
 
1.2  Benefits of the study 
 
Thiamin status appears to be problematic in diabetes, and an understanding of 
thiamins role and metabolism has the potential to normalise some aspects of 
metabolism in diabetes. The role of thiamin in diabetes is currently being researched 
in a jigsaw fashion. 
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 It has been shown that: 
 
• High dose thiamin has a potential role in ameliorating aspects of some 
complications of diabetes and currently several research centres are 
investigating the mechanism and implications of this finding in both animal 
and human studies.  
•  mild thiamin deficiency is prevalent in diabetes, although various studies 
have shown conflicting results as to which markers of thiamin status are 
reduced, and the extent of this reduction.  
• excretion of thiamin in people with diabetes is probably increased in 
comparison to those without diabetes. 
 
There is no definitive research addressing thiamin in diabetes between the mouth 
and the red cell while considering diabetes control. This study addresses that area, 
and differs from other studies by including dietary intake data, and data on other 
possible modifiers of thiamin status. It contributes another piece to the jigsaw and 
adds  to the emerging picture of the role of thiamin in diabetes. The completion of 
this picture has the potential to aid treatment, and hopefully to prevent some 
complications of diabetes. 
 
1.3  Objectives of the study 
 
The study will attempt to clarify the relationship between red cell thiamin levels and 
dietary intake and diabetic control using adequate numbers of subjects to provide 
sufficient power, and also to differentiate between the two types of diabetes.  
 
The primary objectives of the study are, in type 1 and type 2 diabetes, to: 
 
      1.   Determine the relationship between red cell thiamin levels and dietary  
            thiamin. 
2. Determine if red cell thiamin levels are related to diabetic control as 
      measured by HbA1c. 
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The secondary objectives of the study are, in type 1 and type 2 diabetes, to: 
 
1. Validate a method to accurately assess and describe the intake of  
             thiamin, carbohydrate, energy intake, 
2. Assess and describe the intake of thiamin, carbohydrate, energy intake, 
            thiamin per unit of energy and percentage of carbohydrate.       
3. Access and describe other known modifiers of thiamin status; age, BMI,  
      duration of diabetes, activity, smoking status and urinary albumin excretion.               
4. Access and describe indices of diabetic control and its possible 
      modification by episodic hypoglycaemia.   
5. Access and describe thiamin status as measured by serum and red cell 
      thiamin. 
6. Address the relationship of 2, 3 and 4 to 5. 
 
1.4  Limitations of the study 
 
• The thiamin assay used in this study has been well validated and is used for 
all medical thiamin assessments carried out in Western Australia. Non 
parametric reference ranges for both serum and red cell thiamin were 
determined on 505 healthy individuals aged 18 to 90 years.9 Mandatory 
enrichment of bread making flour in Australia since 1991 has increased the 
thiamin content of all breads10 with a concomitant increase in mean thiamin 
intake of 25% in men, and 20% in women in the Australian population.11 In 
those without diabetes and in the absence of excess alcohol, dietary intake of 
thiamin is the main determinant of thiamin status, therefore, it is reasonable 
to assume the reference levels used may now be too low in relation to current 
food supply. If this is so, it would not negate the study results, but would 
increase the numbers of subjects with low serum and red cell thiamin levels.  
 
• Although the objectives of this study  were primarily to examine the effects 
of parameters of dietary intake  and diabetes control on thiamin status, it 
would have added to the completeness of the data to have also assessed 
urinary excretion of thiamin. 
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• Nutrient assessment by 24-hour recall gave good correlation on repeat 
assessment for all nutrients assessed. Testing for agreement was less uniform; 
good agreement was obtained for thiamin intake on original and repeat 
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CHAPTER 2        LITERATURE REVIEW 
 




Thiamin was one of the first organic compounds to be recognised as a vitamin; that is 
as one of  thirteen organic compounds that are identified as being indispensable to 
the healthy functioning of the cells and tissues of the human body. The unique 
feature of the vitamins is that they generally cannot be synthesized by mammalian 
cells and, therefore, must be supplied in the diet. Vitamins occur in small quantities 
in food, and are thus part of the group termed micronutrients, distinguishing them 
from the macronutrient group which includes the compounds present in larger 
amounts in foods. In 1926 thiamin was designated vitamin B1, and is part of the 




Beri-beri was first described by the Chinese in about 2700 BC, but it was not until 
the 1880s that Dr K. Takaki, the Director General of the Japanese Naval Medical 
Services, stumbled upon it again. Takaki tipped a relationship between the diet of 
sailors on naval ships, and the occurrence of beri-beri.14 In 1882 a navy boat returned 
from a 272 day journey with 61% of the crew sick with beri-beri. In 1884, Takaki 
loaded another boat with extra dry milk and meat, and after a 287 day journey, only 
14 of the crew sickened with beri-beri.15 Because of this, Takaki  initially thought 
beri-beri was connected with inadequate nitrogenous substances in the diet of the 
sailors. To combat this he ordered the sailors diets routinely be diversified by 
decreasing the proportion of rice, and increasing meat, fish, barley and vegetables. 
On this diet, over the next six years, the incidence of beri-beri in the Japanese navy 
decreased from 40% to 0%.16 
 
In 1886, Dr C. Eijkman, at a military hospital in Java, discovered that chickens fed 
white polished rice developed an animal form of beri-beri, while those fed unhusked 
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rice did not, and he and a colleague, Dr G. Grijns, concluded there was a substance in 
the outer coating of rice that was necessary for the chickens to maintain health.16  
 
There is present in rice polishings a substance different from protein and salts, 
Which is indispensible to health and the lack of which causes nutritional 
polyneuritis.    C. Eijkman and G Grijns, 190616 
 
Following this, Dr C. Funk, at the Lister Institute in London, crystallized an amine 
substance from rice bran, which he called vitamine, for vital amine. The 
crystallized substance turned out not to be thiamin, but the name stuck. Eventually, 
after more work by several other research groups, two Dutch chemists, Dr B. Jansen 
and Dr W. Donath, crystallized thiamin from rice bran in 1926. They named it 
antineuritic vitamin, however this name was not accepted by the American Medical 
Association (AMA). The correct formula of thiamin was determined by Dr R. 
Williams of the Bureau of Science, in Manila, who was asked by the AMA to come 
up with an alternative name. He chose the name thiamin.15, 16  
 
2.1.2 Structure  
 
The formula of thiamin is C12H17N4OS. The structure of thiamin is a substituted 
pyrimidine ring (a 6 member ring containing two nitrogen atoms at position 1 and 3) 
and a thiazole ring ( a 5 member ring with a sulphur and nitrogen atom at 1 and 3). 
The rings are connected with a one carbon link, or a methylene bridge. The nitrogen 
in the thiazole ring has a positive charge, which makes it serve as an important 
electron sink 16, 17 (see section 2.1.14). Thiamin has a molecular weight of 266.4.18 
 
 
Figure 2.1    The structure of  thiamin16 
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The main biologically active form of thiamin in the human body is thiamin 
pyrophosphate. Thiamin pyrophosphate is also known as thiamin diphosphate or 
cocarboxylase. 
 
Figure 2.2    The structure of thiamin pyrophosphate (TPP)16 
 
Other forms of thiamin found in the body are thiamin triphosphate and thiamin 
monophosphate. 
 
2.1.3   Food sources  
 
The richest food source of thiamin is vegemite (a yeast extract) and brewers yeast, a 
dried, inactive yeast that is a byproduct of the brewing industry. Other foods that are 
naturally occurring good sources of thiamin are pork and bacon, wholemeal bread 
and legumes. Other, less rich, but still significant sources are milk, nuts, oats, 
oranges, brown rice, beef, and some seeds such as sunflower seeds.19 Refined sugar 
contains no thiamin.14 
 
2.1.4   Form 
 
Thiamin can be found in food as the free form, thiamin monophosphate, thiamin 
diphospate (thiamin pyrophosphate) and as a protein phosphate complex. There is 
limited data available on specific forms in specific foods, however, in general, 
thiamin occurs mainly as the free form in plants and phosphorylated  in animal 
tissues1 but the phosphorylated form can also be found in plants.20 Thiamin protein 
phosphate complexes occur in some seeds.21 In milk, the vitamin is present both as 
free thiamin and as a vitamin-protein complex.22   
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2.1.5   Availability from food 
 
Properties 
Thiamin is water soluble, so thiamin is lost into water during water-based cookery. 
Considerable losses of thiamin occur during heat processing of food, especially 
prolonged cooking.15 Estimated average loss in cooking in a mixed diet is 25%.13 
Pasteurization of milk can also result in losses of thiamin of up to about 20%. 
Thiamin is destroyed by x-rays and by ultraviolet irradiation of food stuffs.14 It is 
relatively acid-stable23 and there is little loss from freezing.14 Thiamin has a high rate 
of loss in the extrusion process to make snack foods.24 
Thiaminases 
These are enzymes found in fish and some other organisms which biologically 
deactivate thiamin by splitting the molecule. Thiaminase 1 is the most common and 
is found in some raw fish, shellfish and some types of ferns. Thiaminase 11 is much 
less common and is found in some other organisms, eg types of fungi.14 The process 
by which thiamin is split differs between the two types of thiaminases. Thiaminases 
are destroyed by heat.14 It is almost certain that the explorers Burke and Wills, who 
died in the outback in 1861,  died as a result of eating large quantities of nardoo, an 
Australian fern with a high content of thiaminase 1. Burke and Wills prepared nardoo 
by grinding and cooking it, but as the fern is adapted to the high temperatures of 
central Australia, the thiaminase was not destroyed. The aboriginal people of the area 
also used nardoo, but ground and diluted it with water thus decreasing thiaminase 
activity.25 
 
2.1.6  Fortification of food 
 
Thiamin content of foods can vary with processing. Wholegrain cereal and rice 
products are rich sources of thiamin14, 19, 26  whereas most of the natural thiamin 
content is lost in the production of white flour and polished rice.18 A need was seen 
to ensure adequate thiamin intake in some sectors of the Australian population 
because of the prevalence of  Wernicke-Korsakoff Syndrome. Wernicke-Korsakoff 
Syndrome is a degenerative brain disease associated with a high alcohol intake and 
an inadequate thiamin intake27 (see section 2.1.18). Australia has a high incidence of 
Wernicke-Korsakoff syndrome  compared to other countries.28 In response to this, 
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the National Health and Medical Council (NHMRC) recommended addition of 
thiamin to beer and flagon wine. This was supported by economic analysis but 
opposed by a variety of manufacturing groups, nutritionists and those opposed to 
alcohol.29  
 
The 1983 National Dietary Survey of Adults indicated that bread and cereals were 
the major sources of thiamin intake in the Australian diet so it was decided to fortify 
flour for bread-making rather than alcoholic beverages. An amendment to the 
Australian Food Standards Code was passed in 1991 making it illegal for bread-
making flour to contain less than 6.4 mg/kg of thiamin and thus necessitating the 
addition of approximately 4 mg thiamin/kg to white bread-making flour and 2 mg/kg 
to wholemeal bread-making flour.30  Thiamin that is added to bread-making flour is 
in the form of thiamin mononitrate. The amounts added are approximately 0.5 
mg/100 g for white bread and 0.2 mg/100 g for wholemeal bread. It is premixed with 
a small amount of flour which is then remixed into the larger amount. Thiamin is 
fairly stable at the pH of most breads, which is about 5.31 Loss of thiamin during 
baking varies from 5% to 40%, depending on heat of baking and surface area. The 
thiamin content of both white and wholemeal bread is now 0.45 mg/100 g.32 
 
There has been a significant reduction in the prevalence of  Wernicke-Korsakoff 
syndrome in Australia since the introduction of thiamin enrichment of bread flour, 
although the prevalence is still higher than in most other Western countries.28 There 





Thiamin is available in nutritional supplements. Over the counter thiamin 
supplements are typically found in the form of multivitamin, multivitamin and 
mineral or B-complex preparations. Single ingredient thiamin supplements are also 
available.  The form of  thiamin in supplements is usually thiamin hydrochloride or 
thiamin mononitrate.23  
  - 10 - 
 
 




Figure 2.4    Structure of thiamin nitrate35 
 
 Thiamin hydrochloride is more soluble than thiamin nitrate, but the latter is more 
stable at temperatures less than 95°C.36 The amount of thiamin in supplements varies 
from approximately 1 mg to 50 mg per tablet in some super multi B formulations. 
Lipid-soluble thiamin derivatives called allithiamins are also available. The most 
commonly used is benfotiamin.37 Benfotiamin is CS-benzoylthiamine-o-
monophosphateoral and it would appear that administration of benfotiamin is highly 
suitable for therapeutical purposes (see section 2.1.9).38 
 
Vitamins and/or mineral supplements must conform to the standards set down in the 
specific rules on vitamins and minerals laid down in the Guidelines set out by Food 
Standards Australia New Zealand (FSANZ).  In Australia, vitamin and mineral 
supplements are regulated as complementary medicines under the Therapeutic Goods 
Act 1989 which regulates specific complementary medicines.39 
 
Oral toxicity in humans of thiamin is considered low, although it has been reported 
that oral doses of thiamin hydrochloride of greater than 700 mg have caused 
headache, nausea, rapid pulse and weakness which resolved following reduction in 
thiamin intake. There have been several single case studies of reactions at lower 
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doses than this. No mechanism of toxicity has been identified.23  Some 
hypersensitivity reactions have occurred  after parenteral doses of thiamin. These 
reactions have ranged in severity from very mild to, very rarely, fatal anaphylactic 
shock.37 The NHMRC has determined that there is not enough evidence to set a safe 




Thiamin in food appears to have a high bioavailability.23 A 1997 review on the 
bioavailability of thiamin1 suggests a high, but not total availability of naturally 
occurring and supplemental vitamin sources.1 There is limited data on the 
bioavailability of thiamin from specific foods, however the few studies do support a 
good availability.18 An animal study using pigs on the bioavailability of thiamin in 
eggs, bananas, white cabbage, corn, milk, fish, barley, soybeans, rice, wheat bran, 
brewer's yeast, rye and soybean meal showed a good bioavailability (73% to 94%) 
from all tested foodstuffs. 41  An Indian study showed good bioavailability of thiamin 
from three types of curry leaves.42 
 
2.1.9 Digestion and absorption  
 
Dephosphorylation 
It would appear that phosphorylated forms of thiamin in food are readily 
dephosphorylated before intestinal absorption.1 Prior to absorption, phosphorylated 
forms of thiamin undergo complete hydrolysis involving a number of different 
intestinal phosphatases. Consequently, thiamin found in the intestinal lumen 
following a meal is in the free form.43  
Site of absorption 
Thiamin is absorbed in the small intestine. Thiamin is variously said to be absorbed 
mainly in the jejunum,44  mainly in the jejunum and ileum,14 and maximally in 
the duodenum, with its rate decreasing caudally along the small intestine.43  
Transport through the intestinal mucosa and rephosphoylation  
When the concentration of thiamin in the gut is low, it is absorbed by active 
transport.14 The thiamin transporter is THTR145 and is Na+ dependent.18, 46 
Intracellular phosphorylation appears to facilitate transport by metabolic trapping.1 
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Thiamin is phosphorylated (or rephosphosphorylated)  in the intestinal mucosa 
during absorption.47 The upper level of concentration of thiamin in the gut for active 
transport is in the physiological range, and variously said to be less than 2 µmol/L14 
and less than 1.5 µmol/L.43  At concentrations greater than this, the absorption is by 
diffusion.14 Thiamin is absorbed by passive diffusion in its unionised form.8  
Intestinal transport of thiamin is rate limiting in humans,14 that is, at physiological 
concentrations of thiamin, absorption in the small intestine is by carrier-mediated 
transport which is saturable. At greater thiamin concentrations uptake is by slower 
passive diffusion.23 
Water soluble thiamin supplements 
Water soluble supplements are almost always thiamin hydrochloride and thiamin 
nitrate. Literature reports on transport of thiamin supplements into the gut is a little 
confusing. Thiamin supplements almost ubiquitously contain amounts of thiamin 
well above physiological levels and are therefore largely subject to absorption by 
passive diffusion. It is variously asserted that absorption of thiamin hydrochloride 
and other water-soluble forms of thiamin is dose-dependent23; that humans have a 
rate-limited capacity to absorb water soluble thiamin supplements such as thiamin 
hydrochloride48; that the proportion absorbed of water soluble supplements is very 
low18 and that at a supplementation level of  2.5  5 mg of thiamin, the majority is 
largely unabsorbed.18 Daily absorption is usually limited to a maximum of 8-15 mg, 
although this may be increased by administration of divided doses with food.18 
Animal studies indicate little difference between absorption of different  water 
soluble supplemental thiamin salts, indicating that they have similar potency.49 
Lipid soluble supplements  
Early studies on lipid soluble forms of thiamin were carried out on a disulphide of 
thiamin and allicin that was derived from garlic. This was called allithiamin, and 
appeared to be a highly available form of thiamin.50 Other lipid soluble forms of 
thiamin, such as CS-benzoylthiamine-o-monophosphate (benfotiamin) are better 
absorbed at higher intakes than are water soluble thiamin supplements.38  According 
to some investigators the allithiamins owe their good absorption to their fat-soluble 
property and their ease of transport across the intestinal wall without alteration48 
although  it has been postulated that some other process may be responsible.1  In one 
study benfotiamin had a significantly greater availability than water soluble 
supplements when being administered at 40% of the quantity of the water soluble 
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substances.51 Thornalley states that benfotiamin is a delivery vehicle for thiamin 
monophosphate and is probably absorbed by the RFC-1 transporter.8  
 
2.1.10 Transport around the body and thiamin transporters 
 
Thiamin is transported around the body in both plasma and red blood cells  however 
about 80% is in the erythrocytes.52 An in vitro study has shown that  approximately  
30% 53 of serum thiamin is bound to serum proteins under normal concentration of 
thiamin, and that as serum concentration of thiamin increases, percentage binding 
decreases.53 Thiamin is a cation, and at physiological concentrations is transported 
across cell membranes by high affinity cation transporters.8 Genes for the thiamin 
transporters are members of the SLC19A group of solute carriers. Three genes 
expressing thiamin carriers have been identified: they are SLC19A2 and SLC19A3 
which encode transporters THTR1 and THTR2, respectively, and SLC19A1 which 
encodes RFC-1 which is a folic acid transporter, but also transports thiamin 
monophosphate into cells. At high expression, it may also transport thiamin 
pyrophosphate out of cells. It is widely expressed in the body, but especially in 
mitochondria. THTR1 is expressed on the basolateral surface of the gut, and in 
skeletal muscle, heart, liver, kidney and placenta and appears to be the primary 
transporter. THTR2 is expressed on the luminal surface of gut epithelial cells, and 
kidney, placenta and liver.8 
 
2.1.11 Uptake by erythrocytes 
 
In vitro studies of uptake of thiamin by the erythrocytes in humans show it is 
probably transported by facilitated diffusion, that is by a low capacity carrier 
mechanism that is Na+ independent. Uptake has two different mechanisms, saturable 
and nonsaturable. The saturable mechanism dominates at physiological 
concentrations. Only about 20% of the thiamin taken up by the erythrocytes appears 
to be bound to membrane or intracellular protein.54 A study in humans indicated that 
thiamin and thiamin monophosphate are transported from plasma into the interior of 
the erythrocyte by the two carrier proteins THTR-1 and RFC-1.2 
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2.1.12 Form in the body   
   
Thiamin is present throughout the body as free thiamin, monophosphorylated 
thiamin, diphosphorylated thiamin (thiamin pyrophosphate) and triphosphorylated 
thiamin.23 Plasma and cerebrospinal fluid contain only the free and 
monophosphorylated forms, while erythrocytes contain the free and all 
phosphorylated forms.18, 55 A thiamin binding protein has been purified from rat 
erythrocytes.54 It is also suggested that in the plasma,  thiamin is bound to albumin 
via its phosphate moiety, so that it must be phosphorylated to be able to be bound to 
protein.53  In vitro studies have also shown that free phosphorylated thiamin in 
plasma is rapidly dephosphorylated.56 Thiamin is rapidly converted to the 
phosphorylated form in the tissues.23 Relatively high concentrations are found in 
skeletal muscle, heart, liver, kidney, and brain.14 Within the tissues, therefore, 
approximately 80% of thiamin is thiamin pyrophosphate, which is the main active 
form. Of the rest, 5  10% is thiamin triphosphate, and the rest is divided between 
free thiamin and thiamin monophosphate.18 The liver is the main site for storage. The 
total metabolic pool of thiamin in the human is approximately 30 mg.52 The half-life 
of thiamin in the body is approximately 9.5  18.5 days.18 
 
2.1.13  Excretion 
 
Free phosphorylated thiamin in plasma is rapidly dephosphorylated.56 It, therefore 
appears  likely that protein binding and urinary excretion of thiamin are linked to a 
dynamic process of phosphorylation and dephosphorylation, and that when the 
vitamin is present in increased concentrations it cannot be bound, and there will be 
consequent increased excretion.53 When intake of thiamin is low, virtually none is 
excreted in the urine.18 However, if intake is high, even though a proportionately 
small amount of the thiamin is absorbed by the gut, serum values are elevated and 
result in active urinary excretion.1, 18, 44 Over 200 urinary metabolites of thiamin have 
been identified.1 
 
The proportion of thiamin excreted appears to be dependent, at least partially, on 
whether it is taken orally or administered intravenously (IV). With a 50 mg dose of 
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thiamin hydrochloride, 53% of an IV dose is recovered in the urine within 24 hours. 
With a 50 mg oral dose only 2.5% of the dose was recovered in the urine.57 It is 
postulated this may be due to incomplete intestinal absorption of the thiamin, or 
perhaps retention by body tissues.1 
 
2.1.14    Function in the body 
 
As stated in section 2.1.2, the main biologically active form of thiamin in the human 
body is thiamin pyrophosphate. Ingested thiamin is rapidly converted to thiamin 
pyrophosphate in the brain and liver by a specific enzyme, thiamin 
diphosphototransferase which catalyses the replacement of  the hydroxyl group 
attached to the thiazole group with a diphosphate ester group. Thiamin 
pyrophosphokinase would appear to be an adaptive enzyme whose activity depends 
on the thiamin content of the cells. Its activity is reduced in liver and heart muscle of 
thiamin deficient rats, but no decrease in enzyme activity has been found in the 
brain.58 
 
Thiamin pyrophosphate functions in the body as a coenzyme. Coenzymes are organic 
non protein molecules that bind with the protein enzyme (apoenzyme) to form the 
active enzyme.59 The 2 carbon of the thiazole ring is the reaction site of thiamin 
pyrophosphate. The hydrogen atom attached to this carbon bond readily dissociates, 
leaving a carbanion which is available for nucleophilic  (literally nucleus loving or 







Figure 2.5  Nucleophilic addition to an unsaturated carbon bond to a carbonyl 
                    group16 
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Thiamin pyrophosphate is the coenzyme for two types of enzymes, alpha-ketoacid 
dehydrogenases and transketolases, both of which break a C-C bond next to a 
carbonyl group releasing carbon dioxide or an aldehyde.16  
 
Thiamin, in the form of thiamin pyrophosphate (TPP), is the coenzyme for three 
enzyme complexes that catalyse oxidative decarboxylation reactions; pyruvate 
dehydrogenase in carbohydrate metabolism, alpha-ketoglutarate dehydrogenase in 
the citric acid cycle, and a branched chain keto-acid dehydrogenase that catalyses 
metabolism of leucine, isoleucine and valine; TPP is also the coenzyme for 
transketolase in the pentose phosphate pathway. In all cases, apart from 
transketolase, the carbanion adds to a carbonyl group of the reactant eg  pyruvate, 
which then decarboxylates eliminating CO2.61 
Thiamin in carbohydrate metabolism and the citric acid cycle 
The citric acid cycle is an endpoint of the catabolism of all major products of 
digestion with all the pathways leading to the production of acetyl-CoA, which enters 
the citric acid cycle for complete oxidation to CO2 and H2O.61 

















Figure 2.6   The citric acid cycle is an endpoint (modified from61) 
Carbohydrate Protein Fat 
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Thiamin pyrophosphate is the coenzyme for enzyme complexes that catalyse the 









Figure 2.7    Carbohydrate metabolism and the citric acid cycle showing the  








Figure 2.8    Decarboxylation of pyruvate in carbohydrate metabolism with 






Figure 2.9    Decarboxylation of alpha-ketoglutarate in the citric acid cycle  
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The citric acid cycle takes place in the mitochondria, and is aerobic, that is it requires 
mitochondrial enzymes and oxygen. This is in contrast to glycolysis (prior to the 
citric acid cycle) which takes place in the cytosol of all cells, including erythrocytes 
(which lack mitochondria) and can function aerobically or anaerobically. 
Thiamin pyrophosphate in the pentose phosphate pathway 
The pentose phosphate pathway is an alternative to part of the pathway of glycolysis 
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Figure 2.10    Metabolism of carbohydrate showing glycolysis and the place of 
                       the pentose phosphate pathway61 
 
 
The enzymes for the pentose phosphate pathway, are, like the enzymes for 
glycolysis, found in the cytosol. It is firstly an anabolic pathway that uses the 6 
Citric acid 
   cycle 
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carbons of glucose to generate 5 carbon sugars. However this pathway does oxidise 
glucose.16, 61 
 Its main functions are: 
1. To generate NADPH for biosynthesis reactions within cells.  
2. To provide cells with ribose-5-phosphate for the formation of nucleotides and 
nucleic acids.  
3. And less importantly  it can operate to metabolize pentose sugars derived from the 
digestion of nucleic acids and also rearrange the carbon skeletons of dietary 
carbohydrates into glycolytic/gluconeogenic intermediates.  
The pentose phosphate pathway accounts for 30% of the oxidation of glucose in the 
liver. Erythrocytes also use the pentose phosphate pathway to generate large amounts 
of NADPH used in the reduction of glutathione.17 There are two parts to the 
pathway. The first is an oxidative phase that is nonreversible, and the second is 
nonoxidative and reversible. The oxidation steps occur at the beginning of the 
pathway and are the reactions that generate NADPH. The non-oxidative reactions of 
the pentose phosphate pathway are primarily designed to generate ribose-5-
phosphate for the formation of nucleotides. Equally important reactions of the 
pentose phosphate pathway are to convert dietary 5 carbon sugars into both 6 
(fructose-6-phosphate) and 3 (glyceraldehyde-3-phosphate) carbon sugars which can 
then enter the pathways of glycolysis.17  





Figure 2.11    Thiamin pyrophosphate in the pentose phosphate pathway (modified 
                      from16) 
 
 
2.1.15  Nutrient Reference Values  
 
There are a variety of Nutrient Reference Values (NRV). They are determined from 
varied sources of evidence such as observations of populations, dietary intakes from 
national surveys, extrapolations from other populations, and in the case of thiamin, 
most importantly experimentation.62  
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Estimated Average Requirement (EAR ) is the daily intake level of the nutrient 
estimated to meet the requirements of half the healthy individuals in a particular life 
stage and gender group.62 
 
 The Australian Recommended Dietary Intake (RDI) is the level of intake of  nutrient 
considered by the NHMRC, on the basis of available scientific knowledge, to be 
adequate to meet the known nutritional needs of practically all healthy people. The 
RDI includes a generous amount factored in to accommodate variations in absorption 
and metabolism of thiamin. Therefore the RDI exceeds the actual nutrient 
requirements of practically all healthy persons.62  
 
The NHMRC-endorsed review of NRVs  accepted several ways of estimating 
requirements of thiamin and inadequate thiamin status. These are low urinary 
excretion; low erythrocyte transketolase activity; low erythrocyte thiamin or elevated 
thiamin pyrophosphate effect.40 Urinary thiamin is the most widely used indicator, 
but erythrocyte transketolase activity is often regarded as the best functional test of 
thiamin status. However, erythrocyte transketolase activity has some limitations as it 
can be affected by factors other than diet. Erythrocyte thiamin is more stable in 
frozen erythrocytes, easier to standardise and less susceptible to other factors 
influencing enzyme activity.40 There is little information about the bioavailability of 
thiamin.40 Determination of the Australian RDI was published by the NHMRC in 
1991, and a further revision was published in 2005, as there was a general consensus 
of opinion that there was sufficient new information to warrant another review. 
Thiamin, as a nutrient, was considered a low priority for revision.63 As the main 
function of thiamin is in the citric acid cycle, the pentose phosphate shunt and 
carbohydrate metabolism, the 1991 RDI for thiamin was expressed in terms of 
energy intake, as 0.1 mg/1000 kJ for all ages. This translated to an average intake of 
1.1 mg for adults, which was revised in 2005, as follows: 
The EAR for thiamin for adults were set on the basis of a number of metabolic 
studies using various endpoints.40 Consideration of these studies indicated a 
requirement of at least 0.8 mg/day of thiamin with intakes of 1.0 mg/day being 
marginally adequate for normal transketolase activity and generally adequate for 
urinary thiamin excretion. The EAR for thiamin was thus set at 1.0 mg/day for men 
  - 23 - 
 
and 0.9 mg/day for women based on body size and energy needs. The RDI was set 
assuming a coefficient of variation for the EAR of 10%.  
 
The upper level of safety (UL) for  thiamin intake has not been estimated. There are  
no reports of adverse effects from consumption of excess thiamin from food but there 
were reports from the 1940s of sensitivity to continuous high doses of oral thiamin in 
fortified foods or supplements. There have also been reports of anaphylaxis and 
death after inappropriate parenteral thiamin.40 
 
2.1.16  Determinants of thiamin status  
 
Thiamin deficiency is most often the direct result of poor diet, which is complicated 
by the effects of alcohol.1 Thiamin deficiency may result from inadequate dietary 
intake of the vitamin as well as from decreased absorption, defective transport, 
increased requirements, and enhanced losses.14 
Diet  
The individual on a thiamin-free diet typically depletes in fewer than two weeks.  
Dietary thiamin intake is the major determinant of thiamin status, shown in a study 
on 206 subjects aged 25-64 years from the population of Seychelles,64 a study on 
1108 French citizens of mixed ages,65 and a study on 200 Spanish schoolchildren.66 
All studies related dietary intake directly to thiamin status.   
 Alcohol 
Alcohol affects thiamin uptake and other aspects of thiamin utilization.67 High 
alcohol intake tends to be associated with poor nutritional intake and as thiamin is 
one of the shortest lived vitamins in the body, it is quickly affected. It has been 
shown using thiamin hydrochloride that high alcohol intake and the consequent 
malnutrition causes  inhibition of oral thiamin absorption and that there are direct 
effects of ethanol on intestinal transport of thiamin.27 Also, in vivo studies on rats 
given high levels of ethanol showed a general trend toward a slower thiamin 
pyrophosphorylation and a faster thiamin phosphate dephosphorylation in the small 
intestine, kidney, heart and liver in the presence of adequate thiamin intake.68 It has 
also been postulated that thiamin deficiency in laboratory animals is not only 
associated with brain damage but also with a tendency to consume more ethanol.69 
Low levels of alcohol intake appear to have no appreciable effect on thiamin status.70 
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 Body Mass Index  
The association between thiamin status and BMI is difficult to assess as there are 
very few studies that examine thiamin status with respect to body weight 
independent of dietary thiamin intake. There is some suggestion that obese women 
may have altered storage mechanism for thiamin. An Italian study of obese versus 
normal weight women suggested obese women maintain higher levels of thiamin 
compared to normal weight subjects by storing greater amounts of thiamin in cells 
but had relatively lower levels of extracellular thiamin.71  In contrast a study entitled 
Blood thiamin status and determinants in the population of Seychelles studied  206 
subjects aged 25-64 years with a wide range of BMI. The study showed diet and 
alcohol as the defining determinants of thiamin status, and BMI as having no 
significant influence.64 The situation with respect to the influence on thiamin status 
of excess body weight per se would appear to be far from clear cut.  
Age 
Elderly people would seem at increased risk for thiamin deficiency. Reduced food 
intake, decreased dietary variety, use of medications, and decreased absorption have 
been suggested. In spite of this, studies in Western populations have generally shown 
that most elderly people meet the current recommended intakes for thiamin, but that 
biochemical evidence of thiamin deficiency has been reported in both free living and 
institutionalized elderly people.72, 73 Studies with rats have suggested that age is an 
important factor in the process of thiamin absorption in the small intestine, and that 
thiamin transport rate through the intestinal wall is significantly lower in ageing rats, 
compared to younger rats. 1, 74  Conversely other studies have indicated that age has 
no appreciable impact on thiamin status.70  
Exercise 
Exercise stresses pathways that depend on thiamin, thus the requirements may be 
increased. There are a number of studies on the relationship between thiamin needs 
and exercise, but none are unequivocal.75 
Smoking 
The evidence that smoking affects thiamin status is mixed. Information from the 
1983 Australian Risk Prevalence Survey comparing 1809 smokers and 4395 non-
smokers showed smokers had a significantly lower intake of thiamin than non-
smokers76 and a similar result was obtained from a British study on 3430 teenagers,77 
and a study in the US on 1338 adults in Michegan.78 However a study of 3390 
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Mediterranean subjects showed no impact of smoking on thiamin status70 as did a 
study of 243 young British adults,79 and of 206 adults in the Seychelles.64 Whether 
smoking per se, independent of dietary intake, affects thiamin status does not appear 
to have been determined. 
 
2.1.17  Thiamin intake in Australia  
 
 The majority of dietary surveys in Australia have been carried out post 1983, 
including four national surveys of food consumed. 
 
Table 2.1    Characteristics of major dietary surveys (modified from80) 
 
Year Type of survey Assessment 
by: 
Population surveyed 
1983 National Dietary Survey of 
Adults 
24-h recall 6255 adults (25-64yrs), 
all capital cities 




2196 adults (18+ yrs) 
all states 





National Nutrition Survey 24-h recall  15,348 adults 
 
 
It is difficult to compare these surveys due to sampling and demographic differences, 
collection methods, changes in the nutrient composition database and other essential 
survey differences. The Bridging Study provides guidelines for comparison and 
interpretation of results from different national nutrition surveys with suitable 
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Table 2.2  A comparison of national thiamin intake for adults (2564 y) from the 
1983 National Dietary Survey of Adults and the 1995 National Nutrition Survey 
(modified from81) 








































This shows that the mean intake of thiamin at each survey exceeded the RDI of the 
time for both males and females. The intake at the 1995 survey was greater than the 
1983 survey, as one would expect, with the institution of mandatory fortification of 
bread making flour in 1991, between the two surveys. The 1995 National Nutrition 
Survey showed that greater than 90% of Australian adults exceeded the RDI for 
thiamin.82 
 
2.1.18  Deficiency states and extent of deficiency in adults  in Australia  
 
There is very little thiamin stored in the body, so depletion can occur rapidly, even as 
quickly as 14 to 18 days.12, 67, 83  
Types of thiamin deficiency 
Initial symptoms of thiamin deficiency are gastrointestinal, such as loss of appetite, 
nausea and vomiting.13 Marginal deficiency results in non-specific symptoms such as 
malaise, weight loss, irritability and confusion.52 
 
Beri-beri is the cover-all term for frank thiamin deficiency.13 Wet beri-beri affects 
the cardiovascular system. Dry beri-beri affects the nervous system.12 Wet  
beri-beri is a cardiac failure, unlike that caused by other types of heart disease. It is 
due to intense peripheral vasodilatation caused by accumulation of  lactate. The 
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lactate accumulates because the lack of TPP precludes conversion of pyruvate to 
acetyl CoA.  There is oedema, warm extremities, and usually a normal ECG. Rapid 
response to thiamin treatment confirms the diagnosis. Dry beri-beri affects the 
nerves in the legs and feet. There is loss of sensation in the feet and weakness. 
Unlike wet beri-beri, response to thiamin is slow. 
 
"A certain very troublesome affliction, which attacks men ,  
is called by the inhabitants Beri-beri (which means sheep) 
 I believe those, whom this same disease attacks, with their  
 knees shaking and legs raised up, walk like sheep.   It is 
 kind of paralysis, or rather tremor: for it penetrates the 
 motion and sensation of the hands and feet indeed sometimes the whole body..." 
                                                                                        Jacobus Bonitus, Java, 163016 
 
Wernicke's encephalopathy involves damage to multiple nerves in both the central 
nervous system, brain and spinal cord and nerves to the rest of the body. It is a 
degenerative brain disease largely associated with high alcohol intake.12, 27  The 
mechanism of how alcohol affects thiamin status has been discussed previously 
(section 2.1.16). It is possible to suffer from Wernicke's encephalopathy without 
drinking alcohol.33  Korsakoff psychosis tends to develop as Wernicke's symptoms 
fade and is  part of the same complex as Wernickes encephalopathy. It involves 
damage to areas of the brain involved with memory. Sufferers may try to hide their 
poor memory by confabulations.12 
Extent of thiamin deficiency in Australia 
Beri-beri  was a notifiable disease until 1991. The last figures listed were 302 cases 
(38 Northern Territory and 259 in WA).84 Current figures are not available. 
Wernicke-Korsakoff syndrome has a different pattern. In the 1980s, Australia had a 
higher incidence of Wernicke-Korsakoff syndrome than other comparable countries. 
Australias national incidence of acute Wernicke-Korsakoff syndrome was estimated 
at about 22 cases/100,000 adults per year.85 Thiamin fortification of bread making 
flour was made mandatory in 1991. Numbers of acute cases of Wernicke-Korsakoff 
syndrome were lower in 1992 and 1993 than for any of the years preceding 
fortification.85 Studies of cadavers however, give a different picture, with Wernicke-
Korsakoff syndrome being more prevalent than is indicated by audits of acute cases. 
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A study was carried out in Sydney on the prevalence of  Wernicke-Korsakoff 
syndrome in Australia post thiamin fortification of bread-making flour. Human 
brains were studied in 2212 sequential autopsies carried out in the New South Wales 
Institute of Forensic Medicine between 1 January 1996 and 31 December 1997. 
Wernicke-Korsakoff syndrome was present in 25 people, giving a 1.1% prevalence.28  
 
2.1.19  Dietary assessment of thiamin intake 
 
Overview of available methods 
There are numerous methods of dietary assessment. They are generally divided into 
attempts to obtain either an average intake, such as in assessments by dietary history 
and food frequency questionnaire, or a chronological observation, such as in food 
records or 24-hour recall.86 
Food frequency questionnaire 
This is designed to assess usual eating habits over the longer term. This method is 
expensive but does not require an interview.87  
Dietary history 
This method also attempts to estimate usual food intake over a relatively long period 
of time, is less expensive, but does require an interview.87, 88 Histories are however, 
subject to problems of memory.89 
Estimated food records 
This method records recent dietary intake. If food is weighed, this type of assessment 
is more accurate but requires a minimum level of literacy and a high level of 
motivation in the participants. Subjects completing food records may change their 
eating pattern as a function of being observed. 87, 88 
The 24-hour recall 
This method is often used in cross-sectional studies. It has the advantage of imposing 
less burden on the participants, so compliance is normally high.86 It is also more 
objective, being a retrospective recent record, which precludes subjects altering 
normal eating pattern due to observation.89  It requires a face-to-face interview, and a 
reasonable number of subjects.87 It minimizes the problem of memory, it being 
almost a given that most people remember what they ate yesterday better than they 
remember what they usually eat.89 It is a useful method of nutritional assessment 
when some participants have low levels of literacy, as shown by a WHO study on 
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nutritional intake in 82 subjects in Kenya with varying literacy,90 and another on 
2134 subjects in San Antonio Texas, also with varying literacy.91 It is less useful in 
assessing usual intake than dietary history,86, 87, 92 but its usefulness in this area is 
increased by repeat 24-hour recalls.87 93  
Reproducibility of the 24-hour recall 
Reproducibility refers to the ability of a method to give similar results when 
repeated. Reducing error increases reproducibility.87 
 
Systematic error in 24-hour recall can be reduced by using a standard interviewing  
technique, interviewer training and/or having the same interviewer, using a standard 
method for food data entry and appropriate database for nutrient analysis.94 
 
Random error increases the variance of estimates, and the main source of random 
error in 24-hour recalls is day to day variation in food intake. It is also less in 
estimating nutrients which are present in many foods, and therefore less likely to 
vary from day to day.94 A testretest method is normally used to check repeatability, 
with the same assessment method being used on the same subjects with a similar 
time gap.87 The gap should be short enough to minimize time-related change in food 
patterns, for example, seasonal change, but long enough that the memory of the first 
interview has dwindled, with 4 to 8 weeks being one recommendation.95 The use of a 
single 24-hour recall to assess the usual intake of an individual can be used, but the 
repeatability of the method should be assessed.87 The use of 24-hour recalls generally 
shows greater repeatability in adults than children.96 
Statistical methods for assessing repeatability of 24-hour recall 
Correlation describes the linear relationship between two variables,97 in this case the 
first and second dietary assessment. The correlation coefficient r is a measure of the 
closeness of the relationship between the two sets of assessments. The most 
commonly used are Pearsons product moment correlation coefficient for data with a 
normal distribution and Spearmans nonparametric rank correlation coefficient for 
data with other than a normal distribution.98 Demonstrating a high level of 
correlation between two sets of dietary assessments (by calculating significance) 
shows an association but not necessarily agreement between the two sets of results, 86 
that is, r measures the strength of a relation between two variables, not the agreement 
between them. 
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A Bland Altman Plot is a method described by Bland and Altman in a paper in 
1986.98 Broadly speaking they recommended that an initial plot of the data be made 
and the line of equality drawn on which all points would lie if the two assessments 
were exactly the same every time. They then recommended calculating the 
correlation coefficient (r) to see if the two sets of assessments were linearly related. 
There is perfect agreement only if the points on the plot lie along the line of equality, 
but there will be perfect correlation if the points lie along any straight line. Bland and 
Altman suggested that the difference between the assessments be plotted against their 
means.98 This would allow an investigation of any possible relationship between the 
measurement error and the closest approximation to the true value, which is the 
mean. The lack of agreement would be made clearer by calculating the bias, which is 
estimated by drawing a line parallel to horizontal representing the mean of the 
differences (d). It is assumed 95% of differences will lie between the limits d ± 1.96 
SD (95% confidence intervals or limits of agreement). The standard error of d is then 
calculated as √s2 / n , where n is the sample size, and the standard error of d ± 2s as about 
√3s2 / n.98 Dietmar pointed out the importance of investigating whether the upper or 
lower  95% confidence limit of 1.96 SD of the differences between the methods is 
equal to or smaller than a predefined limit for total error.99 
Thiamin and the 24-hour recall 
Where 24-hour recalls are carefully planned and carried out, and sufficient numbers 
of subjects are interviewed they can give accurate results for many nutrients 
including thiamin.87 This was shown by Kigutha in a study on the nutritional intake 
of 82 subjects in Kenya, where  results for thiamin intake obtained from both 24-hour 
recalls and weighed 3-day food records showed little variation.90 Other examples 
include Munger et al, in two urban areas in the USA,  who showed a good correlation 
between 24-hour recalls and food frequency questionnaires for thiamin (r = .33 for 
micronutrients, including thiamin),100 although correlation with food frequency is a 
less convincing demonstration of accuracy. More convincingly, Sharma et al showed 
good agreement (10% variation) between a single 24-hour recall and weighed food 
records in haemodialysis patients.101 Knapp showed that the use of food models, 
household measures and containers to identify and quantify foods can increase the 
accuracy of  24-hour recalls and give a reasonable assessment of thiamin intake. The 
day of the week is normally a source of variation in 24-hour recalls however this 
appears to have little effect in the assessment of thiamin,102 which may be 
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attributable to the fact that food sources providing thiamin are largely cereal-based, 
which tend to be eaten on a daily basis. Also within-subject errors in nutritional 
assessment are less in the assessment of nutrients present in many foods,87 such as 
thiamin. The converse of this is a study by  Basiotis  showing 24-hour recall can be a 
poor estimate of usual long term intake of thiamin with a minimum of 41 to 46 days 
food records necessary to obtain a true average intake for an individual.103 
 
Overall there is evidence supporting 24-hour recall as a useful tool to assess thiamin 
intake and in view of the fact that thiamin has a  half-life in the body of 
approximately 9.5  18.5 days, estimation of recent dietary intake rather than average 
dietary intake is considered relevant to current thiamin status.18 
 
2.1.20  Biochemical assessment of thiamin status 
 
In humans, there is not, at present, a universally agreed upon direct physiological 
functional indicator of thiamin status.87 In animal studies whole blood thiamin levels 
relate to body thiamin stores although in the early stages of depletion they tend to be 
more depressed than total body stores and  transketolase values underreact during 
early thiamin deprivation. Assessment of  body stores in humans has been more 
problematic.104 The common biochemical tests for assessment of thiamin status are:  
Erythrocyte transketolase activity (ETKA), urinary thiamin excretion, and whole 
blood and red cell thiamin levels.18 
ETKA 
This is probably the most widely used, and is an indirect assessment. Red blood cells 
only have one option for generating NADPH, namely the pentose phosphate  
pathway.  Transketolase which catalyzes reactions in the pentose phosphate pathway 
requires thiamin pyrophosphate. So the level of transketolase activity in the red blood 
cell is a reliable diagnostic indicator of thiamin status. ETKA is determined by 
measuring the disappearance of pentose and appearance of hexose sugars in 
haemolysed red blood cells in the absence, and then presence of excess thiamin 
diphosphate.14 The difference between stimulated activity, and basal activity is 
expressed as a percentage of the basal activity as an activity coefficient or percent 
stimulation.87 Thiamin deficiency is then associated with a decreased ETKA and an 
increased stimulated ETKA.18  
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ETKA, however, has shortcomings. Some diseases cause abnormalities in ETKA. 
Low ETKA has been described in liver disease, uremic nephropathy, cancer, and 
diabetes.105 It has been postulated that low ETKA values in diabetes are due to a 
reduced apoenzyme level.106 Thornalley asserts that the conventional assessment of 
thiamin by the ratio of unstimulated to stimulated ETKA is masked in diabetes by 
increased thiamin transporter content of the erythrocytes.2   Kimura also noted 
reduced activities of glycolytic enzymes in erythrocytes from people with diabetes.107 
Prolonged thiamin deficiency decreases the level of apotransketolase,108 and this will 
also confound the result. Age also can reduce transketolase activity, and there is a 
large within-subject variation in ETKA which makes interpreting transketolase 
activity coefficients difficult.87  
Urinary excretion of thiamin 
In spite of the fact that the US study NHANES 1 used casual urine samples for 
thiamin assessment,109 in subjects with adequate thiamin, urinary excretion does not 
reflect body stores of thiamin,87 but rather is an index of recent dietary intake.14 In 
thiamin deficient subjects, it is not a good indicator of dietary intake or body stores.87  
In addition, most urinary thiamin excretion is in the form of metabolites.87 The 
thiamin loading test involves the measurement of thiamin excreted in urine in the 4 
hours following a 5 mg dose of thiamin. An excretion of < 20 µg is indicative of 
thiamin deficiency.14 This test will detect severe tissue depletion of thiamin.87 The 
most reliable urinary test for recent thiamin intake is the thiamin excretion in a 24-
hour urine sample,33 however the within subject variation is high.87 
Total thiamin or thiamin pyrophosphate in whole blood and erythrocytes 
Early studies were sceptical as to the usefulness of whole blood and erythrocyte 
thiamin as an indicator of thiamin status, however, improved methods have increased 
sensitivity.14 Methods vary, but many involve conversion of thiamin to thiochrome 
and analysis by High Performance Liquid Chromatography (HPLC).105, 110, 111 with 
efficiency improved with semi-automation.110 More recently direct assessment of 
thiamin pyrophosphate by HPLC has been developed and has correlated well with 
ETKA.108 Microbiological methods have also been developed, variously using 
Ochromonas danica112 and Lactobacillus fermenti9 as the test organisms. Good 
correlation between ETKA and erythrocyte thiamin levels has been noted,113, 114 
although the converse has also been shown.115 Erythrocyte transketolase activity has 
some limitations when setting an EAR, as it can be affected by factors other than 
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diet. Erythrocyte thiamin is more stable in frozen erythrocytes, easier to standardise 
and less susceptible to other factors influencing enzyme activity.40 113  Work by 
Herve using a comparison of direct measurement of thiamin and its phosphate esters 
by HPLC and ETKA showed the former to be a more sensitive and specific index of 
thiamin status.115 
Biochemical assessment of thiamin status used in the present study 
Assessment used in this study was an automated microbiological assay of thiamin in 
serum and red cells by the method of  Icke and Nicol.9 This is a microbiological 
assay using Lactobacillus fermenti. This microbiological assay and an established 
thiochrome method were compared by assaying 10 red cell samples by both, and 
correlation was good (r = 0.99), although the microbiological assay gave results 
which were 21-28%  higher than the thiochrome method. Comparisons with serum 
thiamin concentrations were not carried out as  the thiochrome method used was not 
sensitive enough to measure serum, but the concentration of total thiamin found in 
the serum of healthy subjects by this method compared well with concentrations 
reported using sensitive HPLC methods.116 Non parametric reference ranges for both 
serum and red cell thiamin were determined on 505 healthy individuals aged 18 to 90 
years. Ranges were: serum thiamin - 11.3-35-0 nmol/L and red cell thiamin - 190-
400 nmol/L. Results were not related to age or gender and the method was sensitive 




Diabetes is a condition primarily defined as a level of hyperglycaemia giving rise to 
risk of microvascular damage (retinopathy, nephropathy and neuropathy). It is 
associated with reduced life expectancy, significant morbidity due to specific 
diabetes related microvascular complications, increased risk of macrovascular 
complications (ischaemic heart disease, stroke and peripheral vascular disease), and 
diminished quality of life.117 
 
People with diabetes accumulate glucose in their blood, resulting in a high blood glucose 
level or hyperglycemia118 with disturbances of carbohydrate, fat and protein 
metabolism.117 What is termed diabetes mellitus is actually several different metabolic 
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diseases characterized by hyperglycemia resulting from lack of insulin, or a defect in  




Diabetes mellitus is a significant health problem in Australia and throughout the 
world.118 The 2007 figures for the worldwide prevalence of diabetes stand at 246 
million people. This indicates an average of approximately 5.1% of people in the 
adult population have diabetes throughout the world. The projection is that by 2025 
this will increase to 333 million people, bringing the percentage of the adult 
population having diabetes to 6.3%.  Diabetes is the fourth or fifth leading cause of 
death in most developed countries and there is strong evidence that there is an 
epidemic in many developing countries. These estimations are drawn from data 
available for 212 countries and territories.120  
 
The prevalence of diabetes in Australia has been investigated over the last eight years 
by The Australian Diabetes, Obesity and Lifestyle Study (AusDiab Study). The 
AusDiab study was made possible by a $2.6 million grant from the National Health & 
Medical Research Council, with support from state governments, pharmaceutical 
companies and individual donors.121 The AusDiab study is ongoing, with  stage1 being 
carried out in 1999/2000. This stage involved  more than 11,000 people. From this study, 
the prevalence of diabetes in Australia in those aged 25 years and over was estimated to 
be almost one million, many of whom did not know they had the disease. The AusDiab 
2005 study estimated that the incidence of diabetes for Australian adults is 
approximately 275 new cases every day.121 Studies also indicate that the rate of diabetes 
in some Aboriginal and Torres Strait Islander communities is as high as 30%, compared 
to 7% for the non-indigenous population of Australia.122 
 
It has been estimated that there are more than 80,000 people with diabetes in Western 
Australia118. Diabetes as the sole principal diagnosis accounted for more than $5 million 
costs in Western Australian hospital services in 1997-98. This represents only a fraction 
of other morbidities associated with or caused by diabetes, and does not begin to address 
other diabetes- related issues.118 
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2.2.2  Symptoms and signs of diabetes123  
 
Polyuria (frequent urination) 
Polydipsia (increased thirst) 
Unexplained weight loss  
Polyphagia (constant hunger)  
Fatigue 
Slow healing  
Infections  
      Blurred vision 
  
2.2.3   Diagnosis of diabetes 
 
In 1965 the World Health Organization (WHO)  published the first internationally 
agreed guidelines for the diagnosis of diabetes. They were reviewed in 1998. In 
November 2005 a joint WHO and International Diabetes Federation (IDF) Technical 
Advisory Group met in Geneva to review and update the current WHO guidelines. 
In the absence of a more specific biological marker to define diabetes, plasma 
glucose estimation is used as the basis for the diagnosis of diabetes. The criteria are 
based on a level of blood glucose which defines a group of people with a 
significantly increased risk of  premature mortality and microvascular and 
cardiovascular complications.117 
 
The WHO group stresses that the 2 hour post glucose load test, known as the oral 
glucose tolerance test (OGTT), be used preferentially for diagnosis, except where 
circumstances prohibit this, and then suggests using fasting plasma glucose level. For 
clinical diagnosis it is recommended venous blood be used rather than using a blood 
glucose meter, which tests capillary blood, however conversion factors for venous to 
capillary values are given in the WHO criteria.117  
The current WHO diagnostic criteria for diabetes are.117 
-fasting plasma glucose ≥ 7.0 mmol/L (126 mg/dL) 
-2 hour plasma glucose (after a 75 g oral glucose load)  ≥ 11.1 mmol/L (200 mg/dL). 
There is a group of subjects whose glucose levels, although not meeting criteria for 
diabetes, are nevertheless too high to be considered normal.119 The term intermediate 
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hyperglycaemia is sometimes used to define those with blood glucose levels less than 
those diagnostic of diabetes but high enough to be associated with an increased risk 
of diabetes and cardiovascular disease.119 This has also been termed pre-diabetes. 
Pre-diabetes indicates the relatively high risk for development of diabetes in these 
people. People with pre-diabetes are defined as having impaired fasting glucose 
(IFG) and/or impaired glucose tolerance (IGT).124  
The current WHO diagnostic criterion for IFG is: 
fasting plasma glucose ≥ 6.1 mmol/L. 
The current WHO diagnostic criterion for IGT is: 
OGTT ≥ 7.8 and < 11.1 mmol/L.     
(OGTT necessary for  individuals with fasting plasma glucose  ≥ 6.1  6.9 mmol/L). 
 
In the AusDiab study, a cross-sectional survey of adults aged 25 years and older,  
IGT affected 10.6% of subjects, being more common in women (11.9% v 9.2% in 
men), and IFG was present in 5.8%, being more prevalent in men (8.1% v 3.4% in 
women). This represents an overall prediabetes prevalence of 16.4% in Australian 
adults aged 25 years and over. People with prediabetes  have an increased chance of 
diabetes.124 The reported rates of conversion of those with impaired glucose 
metabolism to diabetes vary. However they have been quoted as 64.5% of patients 
with IGT developed diabetes over a follow-up of 5.86.5 years,125 and 32%  within 
3.5 years for IFG.126   
 
2.2.4  History of diabetes127 
 
The first mention of diabetes was in about 1500 BC when Ancient Hindu writings 
spoke of a deadly disease that caused intense thirst, large urine output and wasting 
away of the body. It was attributed to an over indulgence in food and drink, and it 
was recorded that insects and flies were attracted to the urine as it tasted sweet. Over 
the years many remedies were tried, however for thousands of years young people 
with diabetes died quickly, often within days of onset, and older people struggled 
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Table 2.3    Significant events in diabetes (modified from 127) 
 
Date Significant events in diabetes 
1700 
 
Two schools of thought: 1.Sugar lost in urine should be replaced in the diet. 
2. Carbohydrate should be restricted to reduce the sugar in the urine 
1800 First chemical tests to measure sugar in the urine 
1869  Paul Langerhans discovered islet cells in the pancreas islets of langerhans 
1889 Dr Joseph von Mehring and Dr Oskar Minkowski ascertain that removing the 
pancreas causes diabetes. 
1897 Average life expectancy at this time for someone diagnosed at:  
-10 years old  1.3 years 
-30 years old  4.1 years 
-50 years old  8 years 
Usual therapy was a diet < 2000 Kjs daily,  prolonging life by a few months 
1921 Banting and Best discover insulin, a pancreatic extract that lowered blood 
glucose in dogs that had had their pancreas removed. 
1922 Elizabeth Hughes, daughter of the Governor of New York, developed type 1 
diabetes in 1918 and now weighs only 20 kgs. Banting treats her with insulin 
and her recovery is hailed as a miracle. 
1922 Eli Lilly manufacture insulin for use in Australia 
1923 Banting and Macleod win Nobel Prize for Medicine for discovery of insulin 
1940s The link between diabetes and complications was made. 
Life expectancy for a 10 year old diagnosed with diabetes is now 45 years. 
1950 Recommended diabetic diet was 40% fat, 40% carbohydrate and 20% protein 
1955 Two types of diabetes were recognized  type 1 and type 2 and oral drugs 
were introduced to help lower blood glucose levels. 
1959-
1960 
Radioimmunoassay technology shows type 1 diabetes is associated with a 
lack of insulin and research into antibodies to insulin producing cells 
confirms type 1 diabetes is an autoimmune disease. 
1976 Hb1Ac test developed to assess blood glucose in the preceding 3 months. 
1980 Recommended diet was only  30% fat, to help reduce heart disease 
2003 The first islet cell transplantation in Australia is conducted at Westmead 
Hospital on a 37 year old man. 
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2.2.5   Types of diabetes 
 
The vast majority of cases of diabetes fall into two broad categories; type 1 and type 
2 diabetes, however there are many subsidiary types, the main being gestational 
diabetes. The situation is, however, far from clear, as it has happened that type 1 and 
type 2 diabetes can co-occur in the same families, and a possible common genetic 
susceptibility has been mooted.128 There is also evidence that some people have 
insulin resistance as well as anti-islet autoimmunity, perhaps indicating type 2 and 
type 1 diabetes might coexist.129 The level of hyperglycemia reflects the severity of 
the underlying metabolic process and its treatment more than the type of the process 
itself.119 Notwithstanding, the differences being generally marked, the two major 
types of diabetes will be treated separately. 
Definition of type 1 diabetes  
The defining feature of type 1 diabetes is  ß-cell destruction, usually leading to 
absolute insulin deficiency.119  
Definition of type 2 diabetes 
Type 2 diabetes results from a defect or defects in insulin secretion, usually with a 
major contribution from insulin resistance.117 People with type 2 diabetes show 
resistance to the action of insulin but in time there is also a progressive failure of the 
pancreatic beta cells and relative insulin deficiency as well.118 Hyperglycemia 
sufficient to cause pathologic and functional changes in various target tissues, but 
without clinical symptoms, may be present for a long period of time before type 2 
diabetes is diagnosed.119 Although all causes of type 2 diabetes are not known, by 
definition autoimmune destruction of the pancreas does not occur.117 The majority of 
patients with this form of diabetes are obese, and obesity itself causes or aggravates 
insulin resistance. Many of those who are not obese by the criterion of BMI may 
have an increased percentage of body fat distributed predominantly in the abdominal 
region,117 although there is evidence to the converse indicating that BMI and 
measurements of central obesity may have similar associations with incident 
diabetes.130 Certainly, a reduction in weight  per se improves insulin resistance,117  
and a recent study by Haffner over 4 years targeting high-risk nondiabetic 
individuals (n = 3,234) with a mean BMI of 34.0 showed a group with an average 
weight loss of  5.6 kg reduced incidence of diabetes by 58%.131 
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Definition of gestational diabetes (GDM) 
GDM is IGT, IFG or frank diabetes with onset during pregnancy. The definition is 
independent of whether treatment is by diet or insulin and whether or not diabetes 
persists post pregnancy. A review of 28 studies on conversion of GDM to type 2 
diabetes showed cumulative incidence of type 2 diabetes varied widely among 
studies, that progression to type 2 diabetes was highest in the first 5 years after 
delivery. The conversion rates to type 2 diabetes ranged from 2.6 to 70%, over a 
period from 6 weeks to 28 years.132 
 
2.2.6 Demographics of  different types of diabetes 
 
Type 1 diabetes 
People with type 1 diabetes constitute only about 510% of those with diabetes.119  
Throughout the world there is a large variation in prevalence of type 1 diabetes. It is 
postulated this may be partly due to different distributions of genes increasing the 
risk of  the disease as well as variation in possible environmental risk factors. It may 
also be due to methodological problems in determining prevalence in some 
geographical areas.120  
 
In Australia the most recent national estimates of prevalence of type 1 diabetes 
comes from the 2004-05 National Health Survey, which collected self-reported 
information. From this survey it was estimated that 91,900 Australians (0.5% of the 
population) had type 1 diabetes.133 Data collected by the National Diabetes Supply 
Scheme indicates type 1 diabetes is on the increase in Australia.134  
 
In Western Australia, the rate of type 1 diabetes in the 0-14 age group was measured 
in 1983 and showed a prevalence of 59 per 100,000 population and an annual 
incidence of 12.3 per 100,000 population, which is comparable to the rest of 
Australia. In 1998, a total of 740 children and young adults (0-21 years of age) were 
attending type 1 diabetic clinics around the State (Princess Margaret Hospital 
personal correspondence 1998).118 
More recently, the only reliable data on the incidence of type 1 diabetes is in those up 
to 14 years of age for Western Australia, and this also records a significant increase 
in the disease.135 
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Type 2 diabetes 
Type 2 diabetes constitutes about 85% to 95% of all diabetes cases in developed 
countries and an even higher percentage in developing countries.119, 136 There are 
probably many different causes of this form of diabetes.119 Type 2 diabetes more 






Figure 2.12   Self-reported prevalence of diagnosed diabetes by age in Western  
                     Australia.139  
 
In 2007, it was estimated that there were 246 million people with diabetes in the 
adult population in the seven regions of IDF. This means 7.3% of adults aged 20-79 
in all IDF member countries have diabetes.136  The Western Pacific Region and 
the European Region have the highest number of people with diabetes, 
approximately 67 and 53 million, respectively. The highest rate of diabetes 
prevalence is to be found in the North American region (9.2%) followed by the 
European Region (8.4%).136  
 
There is a distinct  impact of migration on the incidence of  type 2 diabetes, which is 
paralleled by the prevalence of obesity in different ethnic groups. The risk escalation 
follows a gradient, as migrants become more affluent and urbanized, indicating an 
important role of environmental factors.137 The determinants appear to include 
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nutrition transition, physical inactivity, and some assert, stress.137 There appear to be 
differences between ethnic groups in their susceptibility to diabetes under the same 
environmental pressure.138 Generally speaking increasing diabetes prevalence is 
projected to occur because of ageing populations, diet, increasing obesity and an 





 Figure 2.13  Differences in the prevalence of type 2 diabetes among two selected 
                      ethnic groups, 2003120  
 
The prevalence of type 2 diabetes in Australia as determined by the AusDiab study 
has been discussed in detail in section 2.2.1. In addition, the Australian Bureau of 
Statistics National Health Survey 2004-05, reports prevalence of type 2 diabetes 
based on self-reported information.139 According to this survey, 582,800 people 
(approximately 3% of the population) reported having type 2 diabetes versus the 
Ausdiab figures of over 7.2% . 122 
 
The rate of diabetes in the indigenous population far exceeds that in the non-
indigenous Australians. The only national estimates of the prevalence of diabetes 
among indigenous people come from population surveys conducted by the Australian 
Bureau of Statistics. The most recent survey is the 2004-2005 National Aboriginal 
and Torres Strait Islander Health Survey, where it was reported that the prevalence of 
diabetes in participating aboriginal people was 6%, with the proportions being  9% 
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for those in remote areas and 5% in urban aboriginal people.140 This means, on age 
adjusted figures, diabetes is approximately 3.4 times more common in indigenous 
than in non-indigenous people. The ratio between indigenous and non-indigenous 
females of 4.1 was higher than that between indigenous and non-indigenous males, 
which was 2.9.140  
  
2.2.7 Differentiation of diabetes types 
 
Once diabetes is diagnosed by blood glucose level it is necessary to determine the 
type of diabetes. The American Diabetes Association Expert Committee has 
proposed an etiologic classification of diabetes as below. 
Type 1 diabetes 
This is divided into type 1A diabetes representing immune-mediated diabetes and 
type 1B a non-autoimmune idiopathic form of type 1 diabetes.129  
Type 1A diabetes 
 In the majority of people with type 1 diabetes autoimmune destruction of the insulin 
producing ß-cells of the pancreas occurs. Autoimmune destruction of  ß-cells is 
related to both genetic and environmental factors that are still poorly defined. The 
increasing incidence of type 1A diabetes is taken to suggest that environmental 
factors are of importance.129  
 
It has been stated  that features of type 1 diabetes do not become evident until most 
of the beta cells are destroyed, with a ballpark figure given of  about 80% destruction 
needed for obvious features of type 1 diabetes to be manifest.141 However other 
sources assert the exact ß-cell mass remaining at diagnosis is poorly defined.129 
People diagnosed with type 1 diabetes are rarely obese; however newly diagnosed 
type 1 diabetes can occur in the obese person.119 Genetic susceptibility to type 1A 
diabetes involves multiple genes.141 
 
Immune mediated diabetes commonly occurs in childhood and adolescence, but it 
can occur at any age, even in the 8th and 9th decades of life.119 It is estimated that, 
among patients with type 1 diabetes, 40% develop diabetes by 15 y of age, 30% 
between 15 and 34 y of age, and 30% thereafter142 The rate of  ß-cell destruction is 
quite variable, being rapid in some individuals (mainly infants and children) and 
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slow in others (mainly adults).119 People with type 1A diabetes are at risk for 
development of thyroid autoimmunity, coeliac disease, Addisons disease, pernicious 
anemia, and a series of other autoimmune disorders.129 
 
Various autoantibodies are markers of  ß-cell destruction. Markers  used for clinical 
differentiation of type 1 diabetes are islet cell autoantibodies and autoantibodies to 
glutamic acid decarboxylase (65) (GAD).143, 144 GAD is the  pancreatic islet beta-cell 
autoantigen which is a major target of autoantibodies associated with the 
development of type 1 diabetes. It is the biosynthesizing enzyme of the inhibitory 
neurotransmitter gamma-aminobutyric acid (GABA). Pancreatic beta cells show high 
levels of this enzyme.145 One and usually more of these autoantibodies are present in 
8590% of individuals at diagnosis of type 1 diabetes.119 The International Diabetes 
Society (IDS) and the Centres for Disease Control have initiated the Diabetes 
Autoantibody Standardization Program143. Roughly 10% of people diagnosed with 
type 1 diabetes on clinical parameters have no relevant autoantibodies.143 
 
It is asserted that insulin resistance plays a larger role in type 1 diabetes than was 
generally thought. As previously stated, the onset of type 1 diabetes is often preceded 
by an illness and/or the onset of puberty, both conditions associated with insulin 
resistance. In the face of beta-cell damage and thus reduced insulin secretion, this 
change is enough to cause  hyperglycemia.146  What is undisputed is, residual 
functional beta cells may still exist but are insufficient in number to maintain glucose 
tolerance. The events that trigger the transition from glucose intolerance to frank 
diabetes are often associated with increased insulin requirements, as might occur 
during infections or puberty.141 After the initial clinical presentation of type 1A 
diabetes, a "honeymoon" phase may ensue during which time glycemic control is 
achieved with modest doses of insulin or, rarely the need for exogenous insulin 
temporarily disappears. As many as 40% of all people diagnosed with type 1 diabetes 
enjoy a remission of some degree after starting insulin treatment147. Remission is due 
to partial functional recovery of the surviving beta cells, whose capacity to secrete 
insulin is impaired by hyperglycaemia itself. It is generally stated that the 
honeymoon often lasts 3-6 months but may continue for 2 years.141 A study on 103 
children less than 12 years of age showed that partial remission occurred in 71, and  
complete remission in 3. The length of time until remission was 28.6 ± 12.3 (mean ± 
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SD) days. The duration of remission was 7.2 ± 4.8 months. Remission rates were 
higher in those patients older than 5 y compared with those between 3 and 5 y of 
age.148 The honeymoon phase ends when the remaining beta cells are finally 
destroyed by the continuing autoimmune onslaught.147 For patients with long-term 
type 1 diabetes, there is often evidence via C-peptide secretion of some ß-cell 
function remaining, although ß-cell mass is usually decreased to less than 1% of 





Figure 2.14   Development of type 1 diabetes141 
 
Type 1B diabetes 
A small minority of patients with type 1 diabetes have no evidence of autoimmunity. 
Most are of African or Asian ethnicity and the diabetes is strongly inherited. This 





  - 45 - 
 
Type 2 diabetes 
People with type 2 diabetes usually have at diagnosis insulin resistance and/or 
relative (versus absolute) insulin deficiency.119 The condition develops insidiously 
and the early symptoms may not be recognised. Subsequent to diagnosis, 
hyperglycemia sufficiently severe to cause damage and alteration in physiological 
behaviour to various target tissues in the body may be present. This may be without 
obvious clinical symptoms, and may precede the diagnosis of diabetes by a long 
period of time, although an abnormality in carbohydrate metabolism can be detected 
by measurement of plasma glucose in the fasting state or after a challenge with an 
oral glucose load.119 
 
Unless picked up incidentally, initial presentation of type 2 diabetes is often with the 
symptoms of hyperglycemia, but may even be with complications of diabetes.149 In 
type 2 diabetes, concordance between identical twins is very high, quoted as 60  
100% (compared to 36% for people with type 1 diabetes), suggesting a much 
stronger genetic component in type 2 than in type 1 diabetes. However, the genetics 
of type 2 diabetes are complex and not well defined.119 
 
The majority of people, but not all, with this form of diabetes are obese. If 
genetically predisposed, the risk of developing this form of diabetes increases with 
age, obesity, and lack of physical activity. It is associated with at least some degree 
of insulin resistance.119 In addition to obesity and family history of type 2 diabetes, 
other features which may help to distinguish  type 2 diabetes are a combination of: 
absence of specific autoimmune markers, especially GAD-65 antibodies; an absence 
of urinary ketones and basal or stimulated C-peptide.150 
 
Because of the prevalence of type 2 diabetes, testing for undiagnosed type 2 diabetes 
is recommended for high risk individuals, including: 
 People with impaired glucose tolerance or impaired fasting glucose; 
 Aboriginal and Torres Strait Islanders aged 35 and over; 
 Certain high risk non-English speaking background groups aged 35 and over 
(specifically Pacific Islander people, people from the Indian subcontinent or of 
Chinese origin); 
 People aged 45 and over who have either obesity or hypertension; 
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 All people with clinical cardiovascular disease and 
 Women with polycystic ovary syndrome who are obese.151 
Differentiation of gestational diabetes 
Gestational diabetes is differentiated as any degree of glucose intolerance which 
commences or is first recognised during pregnancy, regardless of whether insulin or 
only dietary change is used for treatment or whether it persists after pregnancy.119  
 
2.2.8 Complications of diabetes 
 
Diabetic complications are the main cause of morbidity and mortality in those with 
diabetes.152 Poorly controlled diabetes can result in damage to small and large blood 
vessels throughout the body, leading to long-term complications.118 Cardiovascular 
disease (CVD) is the major cause of morbidity and mortality for people with 
diabetes. The common conditions coexisting with type 2 diabetes such as 
hypertension and dyslipidemia are  risk factors for CVD, and diabetes itself is an 
independent risk factor. Microalbuminuria is also a well-established marker of 
increased CVD risk.153 Hypertension is a common comorbidity of diabetes and is a 
major risk factor for both CVD and microvascular complications. In type 1 diabetes, 
hypertension is often the result of nephropathy, while in type 2 diabetes it is usually 
associated with metabolic syndrome.153, 154 
 
Where insulin resistance is present, it is associated with abdominal obesity, high 
blood pressure and high blood fats. This cluster of risk factors predisposes people 
with type 2 diabetes to accelerated microvascular and macrovascular disease.118 
People with type 2 diabetes have an increased incidence of lipid abnormalities, 
mainly low high density lipid (HDL) cholesterol levels and elevated triglyceride 
levels, which contributes to their high risk of  CVD.153  
 
Diabetic nephropathy is a microvascular complication of all types of diabetes and is a 
major cause of early death in these people.149  It occurs in 2040% of patients with 
diabetes and is the single leading cause of all end-stage renal disease155. 
Microalbuminuria has been shown to be the earliest stage of diabetic nephropathy in 
type 1 diabetes and a marker for development of nephropathy in type 2 diabetes.153  
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Diabetic retinopathy is a microvascular complication of both type 1 and type 2 
diabetes. Diabetic retinopathy is the most frequent cause of all blindness among 
adults aged 2074 years. People with diabetes are also more prone to glaucoma and 
cataracts than those without diabetes.153 Diabetic neuropathy is another 
microvascular complication of diabetes where effects on nerves can be acute or 
chronic and where cranial, peripheral and autonomic nerves can be affected.153 
 
In 2004, 11,735 deaths in Australia were related to diabetes. Where diabetes was 
cited as an underlying cause of death, coronary heart disease (CHD) was listed as an 
associated cause in 52.3% of cases, kidney failure in 25.3%, heart failure in 18.5% 
and stroke in 17.2%. When diabetes was listed as an associated cause, CHD was 
listed as the underlying cause of death in 30.5% of cases and stroke in 7.5% of 
cases.139 
 
The causes of the complications of diabetes are the subject of ongoing research. 
Body glucose metabolism uses a variety of  metabolic pathways, therefore chronic 
hyperglycemia can induce diverse cellular changes.152 Genes also play a role in 
processes leading to diabetic complications, as does duration of diabetes,156 and there 
is some suggestion that increased oxidative stress may have a role in the 
pathogenesis of diabetic complications.157  
 
The Diabetes Control and Complications Trial (DCCT) was a clinical study 
conducted from 1983 to 1993 by the National Institute of Diabetes and Digestive and 
Kidney Diseases. The DCCT involved 1,441 volunteers with type 1 diabetes and 29 
medical centres in the United States and Canada. Volunteers had diabetes for at least 
1 year but no longer than 15 years. It showed that that keeping blood glucose levels 
as close  to normal as possible reduces risk of eye disease by 76%, kidney disease by 
50%, nerve disease by 60%.158 
 
The second study targeted people with type 2 diabetes. The UK Prospective Diabetes 
Study (UKPDS) was a 20-year trial which recruited 5,102 people with type 2 
diabetes in 23 clinical centres in the UK. The UKPDS has shown that: better blood 
glucose control reduces the risk of major diabetic eye disease by 25% and early 
kidney damage by 33%. It also showed better blood pressure control reduces the risk 
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of death from long-term complications of diabetes by 33%.  Hyperglycaemia and 
hypertension are independent risk factors for diabetic complications in people with 
type 2 diabetes.159 Epidemiological analyses of the DCCT and UKPDS demonstrate a 
curvilinear relationship between markers of diabetic control and microvascular 
complications, and suggest that, generally speaking, the greatest number of 
complications will be avoided by improving diabetic control from very poor to fair or 
good control.153   
 
2.2.9  Treatment of diabetes  
 
There is no cure for diabetes, but effective treatment exists. This entails keeping 
blood glucose levels as close to the non diabetic range as possible with a 
combination of diet, activity and medication.160 Clinical recommendations are that 
people with diabetes should receive care from a physician-coordinated team.153 Care 
is aimed at minimising symptoms of diabetes and long term complications.  
 
In type 1 diabetes recommended treatment is use of multiple dose insulin injections 
incorporating basal to control glucose produced by the liver and boluses of short 
acting insulin to cover food, all given subcutaneously. Insulin pump therapy using 
short acting insulin only is also available. It is necessary to dovetail insulin, 
carbohydrate intake and activity.153 The development of analogue insulins  has made 
it possible to overcome some limitations in the pattern of action of conventional 
insulins. Insulin therapy needs to be individualized161 Diabetes education should be 
part of the management of type 1 diabetes.162 
 
Therapy for type 2 diabetes, a consensus statement by the American Diabetes 
Association (ADA) and the European Association for the Study of Diabetes on 
individuals with type 2 diabetes states that control of hyperglycemia, the visible 
metabolic abnormality associated with type 2 diabetes, is paramount in context with 
treatment of  obesity, insulin resistance, dyslipidemia and hypertension.163, 164 
Recommendations are immediate intervention at diagnosis with lifestyle changes and  
metformin.163 People with diabetes should be advised to perform at least 150 minutes 
per week of moderate-intensity aerobic physical activity, if medically able. They 
should receive individualised medical nutrition therapy, preferably provided by a 
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dietitian familiar with diabetes.153 They should receive continuing timely review of 
therapy and addition of other agents as needed, including initiation of insulin 
therapy.163   
 
2.2.10 Markers of diabetic control 
 
Monitoring glycemic status is essential in the management of diabetes.165 The main 
techniques used to assess glycemic control are patient self-monitoring of blood 
glucose (SMBG) and haemoglobinA1C measurement (HbA1c). In addition, in recent 
years technologies for continuous monitoring of interstitial glucose have entered the 
market.153 Blood glucose testing provides essential information for day-to-day 
management of diabetes.165 Measurement of HbA1c is a longer term measure 
complementing day-to-day SMBG.165 It is a series of stable haemoglobin 
components formed slowly and nonenzymatically from haemoglobin and glucose. 
The rate of formation is directly proportional to glucose concentration in the blood. 
Because erythrocytes are permeable to glucose, the level of HbA1c is an indicator of 
the glucose level over the previous 120 days, which is the average lifespan of an 
erythrocyte.165  Glycohaemoglobins were first used in routine clinical laboratories for 
diabetes monitoring around 1977. Over the last few years the International 
Federation of Clinical Chemistry Working Group on Standardisation of HbA1c has 
been establishing International Reference Methods for HbA1c.166  
 
There are 3 basic types of assay currently commercially available; immunoassay, 
such as DCA2000 which is used for point-of-care testing used in WA by Princess 
Margaret Hospital; cation exchange, used by Sir Charles Gairdner  and Royal Perth 
Hospitals, and  affinity chromatography, which is considered to have the least 
problems with interference and abnormal haemoglobin variants (expert opinion). 
Results of methods using different assay principles show excellent correlation, and 
there are no convincing data to show that any one method is clinically superior to any 
other.165 Mathematical modelling and in vivo studies have shown that a large change 
in mean blood glucose is accompanied by a large change in HbA1c within a matter 
of 12 weeks, however large variations in blood glucose levels will show an 
unrepresentative HbA1c and therefore frequent hypoglycaemia skews HbA1c.165 
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HbA1c is normal if it is 5% or less. Normal ranges may vary slightly depending on 
the laboratory used.12 The correlation between HbA1c  levels and outcome risks was 
demonstrated in the DCCT and the UKPDS.159, 167 However recent work has shown 
that individual biological variation in HbA1c, distinct from that that can be attributed 
to blood glucose levels, was evident among type 1 diabetic patients in the DCCT and 
was a strong predictor of risk for diabetes complications.168  
 
In diabetes, lowering HbA1c to 7% or less has been shown to reduce microvascular 
and neuropathic complications of diabetes and, possibly, macrovascular disease, but 
epidemiologic studies have suggested a benefit to a HbA1c  of  less than 6%.153  
 
2.3 Thiamin and diabetes 
 
 
People with diabetes accumulate glucose in their blood, resulting in a high blood glucose 
level or hyperglycemia.118 Thiamin plays a major role in glucose metabolism and 
appears problematic in diabetes in a number of aspects. 
 
2.3.1  Blood levels of thiamin in diabetes 
 
 
There are mixed reports in the literature on the status of blood, plasma, and red cell 
thiamin levels in those with diabetes. The concentration of thiamin in red blood cells 
is approximately 12 times that in plasma. Numerous reports have cited a greater 
incidence of suboptimal blood thiamin levels in those with diabetes compared to non 
diabetics.3, 4, 170-172 Thornalley et al report in a recent study, plasma thiamin 
concentration decreased 76% in type 1 diabetes and 75% in type 2 diabetes compared 
with people without diabetes, and these decreased levels correlated with increased 
urinary clearance of thiamin2.  Conversely there are reports of normal blood thiamin 
levels in diabetes in humans5, 173 and in animal studies.174 Haugen showed low blood 
levels of thiamin in type 1 diabetes and normal levels in type 2 diabetes.175 Hobara, 
in a study on animals and humans with diabetes, documented that blood levels of 
thiamin increased as glucose levels increased.169 
 
There is little apparent reason for the variance in study results. Studies showing 
reduced blood thiamin levels in diabetes were carried out variously on animals, 
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adults and children, including those with type 1 and type 2 diabetes (with some 
studies not specifying diabetes type). Subjects in studies showing normal levels of 
thiamin varied similarly. Methods of assessment of blood thiamin varied, being 
mainly thiochrome method or microbiological in older studies, and high performance 
liquid chromatography in more recent studies, but with no particular trend in results. 
The two most recent papers supported reduced blood thiamin levels in diabetes.    
 
2.3.2 Thiamin transport across membranes in diabetes 
 
The transport of thiamin across membranes in people without diabetes has been 
reviewed in section 2.1.10. There appear to be some abnormalities in diabetes. 
It has been shown that a mutation of the gene SLC19A2 causes malfunction of the 
thiamin transporter THTR1, resulting in thiamin deficiency and thiamin responsive 
megaloblastic anemia, and it is thought this may be similar in diabetes.8 
Experimental evidence suggests thiamin and thiamin monophosphate transport may 
be abnormal in diabetes and there is therefore decreased uptake from the gut of these. 
It is also suggested that mild thiamin deficiency in diabetes may induce increased 
expression of the thiamin transporters THTR1 and THTR2, to increase tissue 
scavenging of thiamin and a decrease in the expression of transporter RFC-1, to 
retain tissue thiamin pyrophosphate.8  
 
2.3.3  Thiamin excretion in diabetes 
 
Thornalley found evidence of increased renal clearance of thiamin, with a 24 fold 
increase in type 1 and a 16 fold increase in type 2 diabetes. Plasma thiamin levels 
were negatively correlated with renal clearance.2 It is thought that the development 
of thiamin deficiency with increased renal clearance and albuminuria in diabetic rats 
may indicate abnormal renal handling of thiamin, and may be an early sign of 
declining renal function in diabetes.8  
 
 2.3.4  Other aberrations in metabolism in diabetes relating to thiamin 
 
As well as reports of suboptimal thiamin blood levels, there is also evidence of 
suboptimal activity of the thiamin dependent enzyme erythrocyte transketolase in 
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diabetes.3, 105 It has been postulated that these low levels are due to a reduced 
apoenzyme level.106 Transketolase has a short half-life (about 25 minutes) in the 
absence of thiamin pyrophosphate, so decreasing thiamin pyrophosphate decreases 
the activity of transketolase.8  Thornalleys work has indicated that ETKA is not 
significantly reduced in diabetes and showed a thiamin stimulation effect of less than 
15% in people with diabetes, indicating they were technically not clinically thiamin 
deficient. His work showed a masking of clinical thiamin deficiency in erythrocytes 
by increased thiamin content of erythrocyte membrane transporters THTR-1 and 
RFC-1 in both type 1 and type 2  diabetes.2 Kimura noted reduced activities of 
glycolytic enzymes in erythrocytes of people with diabetes.107  
 
As well as abnormalities in blood levels and enzymes, animal studies in diabetic 
animals have shown low levels of thiamin in liver and heart compared to non 
diabetic animals176 and Ariaey-Nejad  has shown increased glucose turnover causes 
increased utilization of thiamin.177 Much research is being carried out in the area of 
thiamin and diabetes. Present results are confusing, but certainly highlight the 
presence of abnormal handling of thiamin in diabetes.  
 
2.3.5  Dietary intake and blood levels   
   
BMI and age can be minor modifiers of blood thiamin levels but in non diabetics, in 
the absence of excessive alcohol, a suboptimal blood thiamin level is normally a 
marker of inadequate dietary intake1 and one would presume that the same situation 
would prevail in those with diabetes. With the documented frequency of  low blood 
thiamin levels in diabetes, it could therefore reasonably be presumed that there is a 
high incidence of low dietary thiamin intake in those with diabetes. However, it has 
been shown in a study of 50 people with type 2 diabetes that dietary intake of 
thiamin was greater than the RDI in 98% of cases,6 and similar results have been 
shown in a study on the nutritional content of subject-selected diets in people with 
type 1 diabetes.7 Saito, in a small study, reported no correlation between normal 
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2.3.6  Results of thiamin supplementation in diabetes 
 
Thiamin supplementation in diabetes appears to have mixed outcomes. A study of 
women with treated GDM found low blood thiamin levels in 19 of the 77 
pregnancies after thiamin supplementation. Babies born to those mothers with low 
blood thiamin levels also had low blood thiamin levels.178 Valerio et al  showed  that 
the plasma content of thiamin and thiamin monophosphate in patients with type 1 
diabetes was significantly lower when compared with these measures in age-matched 
normal subjects after 3 months thiamin supplementation.179 Conversely, Kodentsova 
showed an improvement in blood thiamin level with vitamin enriched drinks in 
children with type 1 diabetes180 and a separate study has shown that ETKA can be 
increased by pharmacological doses of thiamin.181 
 
2.3.7 Thiamin and diabetic complications  
 
It is well accepted that complications of diabetes are related to sustained increased 
blood glucose levels.118 One theory is an increase in cytosol glucose results in 
accumulation of triose-phosphates, which are a potential trigger for biochemical 
dysfunction associated with diabetic complications.8 The triose-phosphates would 
normally be disposed of by the pentose phosphate pathway, however, in diabetes, 
this pathway is impaired by mild thiamin deficiency which decreases the activity of 
transketolase.8 This is consistent with the fact that a significant number of studies 
have shown that some complications of diabetes benefit from thiamin 
supplementation182-186 and that the benefit is not via an improvement in blood 
glucose levels. This is further supported in a study by  Valerio et al which showed 
thiamin supplementation had no effect on HbA1c.179 
 
Increased bioavailability and dose of thiamin supplementation may enhance the 
effect on complications. Some studies have used lipophilic preparations of thiamin, 
such as benfotiamin, to increase the bioavailability. Karachalias et al showed in 
animal studies that high dose benfotiamin therapy countered incipient 
nephropathy.187 Conversely they also showed high dose thiamin, and not benfotiamin 
countered diabetic dyslipidemia.182 In another animal study Stracke showed 
benfotiamin reduced functional damage and the formation of advanced glycation end 
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products (AGE) associated with nerve damage in nerves of diabetic rats.188 Winkler 
et al showed a differential in therapeutic benefit on painful diabetic neuropathy of 
benfotiamin according to dose. Higher dose benfotiamin showed greater efficacy.186 
However, conversely, studies in diabetic rats have indicated that benfotiamin is a 
better deliverer of thiamin in normal rats than in diabetic rats.8 Generally, it appears a 
larger proportion of research is being carried out using benfotiamin, rather than water 
soluble thiamin, but the benefits are certainly not clear cut.  
 
Bender noted that the metabolism of glucose is deranged in thiamin deficiency, but 
once any deficiency has been corrected there is no further effect of increased thiamin 
intake on the ability to metabolize glucose.189 A study by Abbas and Swai showed 
blood thiamin levels were directly reduced proportional to the severity of symptoms 
in diabetic peripheral neuropathy.190 Conversely, as quoted previously, Hobara, in a 
study on animals and humans with diabetes documented that thiamin blood levels 
increased as glucose levels increased.169 As increased glucose levels are associated 
with diabetic complications, the last two studies appear contradictory. Thornalley has 
shown that plasma thiamin and thiamin excretion correlated negatively with vascular 
adhesion molecule, plasma sVCAM-1, which is increased in diabetes and is a marker 
of vascular disease.2 Again, there appears to be no particular effect of thiamin upon 
blood glucose levels. Overall, the relationship between thiamin and diabetic 
complications is a work in progress.  
 
2.3.8  Possible mechanism by which thiamin relates to diabetic complications 
  
A possible mechanism for the effect of thiamin on diabetic complications has been 
put forward by Hammes  from a study using bovine aortic endothelial cells and is as 
follows: of the 4 metabolic pathways related to hyperglycemia-induced diabetic 
complications, 3 are activated by increased availability of the glycolytic metabolites: 
glyceraldehyde-3-phosphate and fructose-6-phosphate. The pathways are the 
hexosamine pathway, the AGE formation pathway and the diacylglycerol (DAG)-
protein kinase C (PKC) pathway. Glyceraldehyde-3-phosphate and fructose-6-
phosphate are also end products of the pentose phosphate pathway, and the activity 
of transketolase determines the rate in this pathway.181 Transketolase has been shown 
to have reduced activity in diabetes.3, 105 If thiamin pyrophosphate availability is 
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optimal, this increases the activity of transketolase which diverts metabolites into the 
pentose phosphate pathway.181 In another in vitro study on human red blood cells in 
the presence of hyperglycemia, Thornalley et al demonstrated that adding thiamin 
increased the activity of transketolase, and decreased triose-phosphates and methyl 




Figure 2.15  Possible mechanism by which increased thiamin blocks pathways of  
                     hyperglycaemic damage (modified from181) 
 
Hammes et al theorise that hyperglycemia may cause functional thiamin deficiency 
in vascular endothelial cells, and while the mechanism is unknown, it may be that 
hyperglycemia renders  these cells unable to downregulate glucose transport 
resulting in increased intracellular glucose and superoxide which oxidises thiamin to 
biologically inactive thiochromes.181  Ascher et al demonstrated in another in vitro 
study that pharmacological amounts of  thiamin reverse endothelial damage in the 
presence of high blood glucose levels,192 and similarly La Selve, showed that thiamin 
corrects cell replication and decreases AGE products in human umbilical vein 
endothelial cells cultured under high glucose.193 Thornalley, in a review paper, 
asserts that thiamin supplementation prevented multiple mechanisms of biochemical 
dysfunction: activation of protein kinase C, activation of the hexosamine pathway, 
increased glycation and oxidative stress, thus preventing incipient diabetic 
nephropathy, neuropathy and retinopathy.8   
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CHAPTER 3        METHODS 
 
3.1 Study population - The Royal Perth Hospital Diabetic Clinic Diabetic 
       Survey 
 
This project was carried out in conjunction with, and based on, participants in the 
Royal Perth Hospital Diabetic Clinic Diabetic Survey. The Diabetic Survey functions 
as a clinical review, designed to identify early indicators of morbidity allowing 
timely intervention, and also functions as a base for research. The Diabetic Survey 
was initiated by Dr John Calder in the late 1960s. Computer records, and a database 
of enrolled patients  commenced in 1973, allowing better organization and access to 
survey results and the recall of participants on a two yearly basis. Participants 
comprise selected patients with type 1 and type 2 diabetes attending the Royal Perth 
Hospital Diabetic Clinic. Selected private patients of diabetic clinic physicians are 
also enrolled. Patients are placed on the survey data base at the discretion of the 
treating physician. Exclusion criteria for selection are: diagnosed with diabetes for 
less than one year, significant other comorbidities, alcohol abuse, and aged over 70 at 
entry. 
 
Diabetic Survey runs every Thursday morning with patients attending from 7 am 
until approximately midday. Patients attend fasting; are weighed, measured, vision 
tested and then have a barrage of blood tests. After breakfast, they attend a diabetic 
physician for a complete medical review, then non-fasting blood tests, and reviews in 
cardiology and opthalmology. Results of blood tests are entered on the hospital 
database (i Soft) and also on the Diabetic Survey database. All other parameters, 
including lifestyle factors, are entered only on the Diabetic Survey database. Apart 
from urgent problems, little medical intervention takes place at Diabetic Survey. 
When all results are available, patients are recalled for follow-up tests, dietary 
counselling where applicable, and a summary of results is sent to the patients 
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3.2  Research design 
 
This study was cross sectional, designed to look at factors affecting thiamin status in 
people with type 1 and type 2 diabetes. The major factors analysed were dietary, with 
data for other possible minor modifiers of thiamin status, including diabetes control, 
being accessed. 
 
3.3  Subjects 
 
3.3.1 Subject selection 
 
Initial subjects were consenting patients with type 1 and type 2 diabetes attending the 
Diabetic Survey. Patients were selected consecutively on the day of attendance at 
Diabetic Survey and oral and written information was given on the study aims (see 
appendix 1), the information that would be required from participants, the results that 
would be accessed and the approval of the study by Royal Perth Hospital and Curtin 
University ethics committees. A consent form was then signed by subjects who 
agreed to participate (see appendix 2). Additional subjects were consecutive 
consenting patients with type 1 and type 2 diabetes on thiamin supplementation. Data 
obtained was as for initial patients, with the exception of a dietary assessment.  
 
Exclusion criteria were:  
• Daily alcohol intake of greater than 4 standard drinks for males and 2 
standard drinks for females: Alcohol affects thiamin uptake,67 and may affect 
other aspects of thiamin utilization such as on oral thiamin transport, and 
intestinal pyrophosphorylation and dephosphorylation.27 Low levels of 
alcohol intake appear to have no appreciable affect on thiamin status.70 
Alcohol and thiamin have been discussed in section 2.1.16. Alcohol intake 
was self reported. 
• Significant other comorbidities: Excluded from this study as significant 
comorbidities may have an independent direct or indirect effect on thiamin 
status. Already excluded from Diabetic Survey Database. 
• Pregnancy or lactation: This alters thiamin metabolism. Pregnancy and 
lactation were self reported. 
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• Currently on antibiotics: interferes with microbiological assay for thiamin. 
Antibiotic status was self reported and cross checked on survey records. 
• Unable to give a 24 hour food recall. 
 
3.3.2  Sample size 
 
The sample size for initial subjects was estimated based on the results of a previous 
small study by SV (prior to her Master's enrolment) and a colleague where dietary 
intake of thiamin was assessed and compared in 40 people with diabetes, 20 with 
normal serum thiamin levels and 20 with reduced serum thiamin levels.194 A  power 
calculation showed a sample size of 43 subjects in each group (type 1 and type 2 
diabetes) would have 80% statistical power to detect a correlation of  at least  0.4  
between dietary intake of thiamin and red cell thiamin levels based on a 5% level of 
significance for each group. 
 
 The sample size for the secondary subjects was estimated based on the results of the 
initial subjects which showed a trend with thiamin supplementation which did not 
reach significance with the numbers in the initial sample. A power calculation 
showing an extra 30 subjects on thiamin supplements was calculated to have 80% 
statistical power to detect an association between the presence or absence of thiamin 
supplementation on attainment of normal red cell thiamin levels based on a  5% level 
of significance.   
 
Data collection for initial subjects took place from 23/2/2006 to 25/5/2006. Two 
potential subjects were excluded, one was on antibiotics and one was pregnant. A 
total of 89 subjects  signed consent forms (44 type 1 diabetes and 45 type 2 diabetes). 
Consent was obtained from 98.9% of the potential sample, with 1.1% (1 subject) 
declining participation. Data collection for secondary subjects took place from 
25/1/2007 to 22/11/2007. Data collection ceased with an additional 24 supplemented 













  unsupplemented                  Supplemented                        Additional subjects 
      (n = 70)                            ( n = 19)                                    (n = 24) 
 
Total supplemented (n = 43) 
 
Figure 3.1  Subjects 
 
3.4.  Methods 
 
Data was collected and accessed primarily to assess the effect of dietary variables 
and diabetic control on serum and red cell thiamin levels in diabetes. Other variables 
that were potential minor modifiers of thiamin status were also included.  Data 
collected or accessed were: demographic variables: weight, height, gender, age, 
smoking status, level of activity, diabetes type and duration, diabetes treatment; 
dietary assessment: intake of thiamin, carbohydrate, energy and alcohol. Blood test 
results: red cell thiamin, serum thiamin, HbA1c; and urinary albumin excretion. Self 
report: average number of hypoglycaemic episodes per week (hypos), currently 
taking thiamin supplements. Data was entered on a standard sheet (see appendix 3). 
 
3.4.1  Demographic variables 
 
All weights were measured to the closest 0.1 kg, on the same digital platform scales 
accurate to 200 kg (Wellsweigh Model JIS  200, First In Scales, Perth, West 
Australia). Heights were measured to the closest 0.1 cm using an adult height 
measure (Pharmacia  Stadiometer, Perth, Western Australia), using standard 
procedure. Smoking status and activity level were self-reported. Diabetes type was 
assigned by the presence of anti-islet antibodies, anti-gad antibodies (indicating auto 
immune destruction of ß-cells thus type 1 diabetes), level of C-peptide (high levels 
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indicating high levels of insulin production, therefore probably type 2 diabetes) and 
clinical judgement by examining physician. Duration of diabetes was as per recorded 
medical diagnosis, and thereby unreliable in type 2 diabetes where diagnosis may 
come years after the onset of symptoms. Diabetes treatment was as recorded by the 
examining physician at onset of interview. 
 
3.4.2 Dietary Assessment 
 
Rationale for use of 24-hour recall 
General pros and cons regarding the use of 24-hour recall and thiamin assessment 
have been discussed in section 2.1.19. The 24-hour recall is relatively easy both in 
time and complexity, so has a high level of compliance,86 requires a face to face 
interview, and a reasonable number of subjects.87 From a practical point of view it 
was eminently suited to the Diabetic Survey, where participants have extended 
periods of time between other tests, interview rooms are available, and potential 
participant numbers are suitable. Royal Perth Hospital services a socially and 
ethnically mixed population with diverse literacy and linguistic levels and it has been 
shown that 24-hour recall is a useful method of nutritional assessment where some 
participants have low levels of literacy,90 with the interview situation allowing 
information to be transmitted orally, details can be clarified and visual aids such as 
food models are available. Kigutha,90 Munger100 and Knapp91 showed the 24-hour 
recall was suitable for assessment of thiamin intake and correlated with other 
methods of dietary assessment.  
Procedure for the 24-hour recall  
A standardised procedure was followed86: 
• Subjects were given no prior warning they would be interviewed regarding 
their food intake at the Diabetic Survey, thus eliminating alteration of food 
habits due to observation, and increasing objectivity. 
• Interviews took place in a relatively quiet room in the diabetic clinic, with the 
door closed. 
• Survey participants with poor English were assigned an interpreter for the 
morning of the Diabetic Survey, and these were available for the 24-hour 
recall interview. 
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• As participants came in fasting and were provided with a (probably atypical) 
breakfast by the hospital at the completion of fasting blood tests, the 24 hour 
recall commenced with the first food of the previous day after midnight and 
proceeded chronologically through until midnight of the night preceding 
Diabetic Survey. All interviews was conducted by the same dietitian (SV) 
and recorded on a standard form (see appendix 4).  
• To help ascertain portion sizes and food constituents, food models, standard 
measuring cups and commercial containers of common foods (eg empty tins 
and packets) were used.  
• Participants were questioned on food preparation and food processing 
methods. 
• Where recipes were other than standard, recipe ingredients were ascertained. 
Where recipes could not be recalled, follow-up information was sought, with 
participants being requested to post, fax, email, or phone through recipe 
constituents.  A reminder letter was sent where applicable. 
• Where commercial foods were unknown, eg culturally specific foods, 
participants were asked to bring in, or send food containers pertinent to these 
foods.  
• Fast food outlets were contacted or accessed on the World Wide Web, pages 
from Australia, to ascertain food ingredients where necessary.  
• To cross check, an average weekly intake of several high thiamin foods was 
also assessed, viz: vegemite, nuts, sports or high protein supplementary 
drinks and vitamin supplements containing thiamin. 
Reproducibility of 24-hour recall 
Reproducibility was assessed by repeat 24-hour recalls on 31 subjects. This 
comprised all initial subjects who were willing to give a repeat recall (34.8% of 
initial subject pool).These were assessed for repeatability of thiamin, carbohydrate 
and energy intake.    
Dietary Analysis 
The 24-hour recalls were entered into the computer dietary analysis package 
Foodworks (Xyris Software, 2006) by the same dietitian who obtained the 24- hour 
recalls. Foodworks defaults to AUSNUT99  database (released by Australian New 
Zealand Food Authority in 1999) which is a compilation of seven data files 
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containing data on the food and nutrient composition of Australian foods. 
AUSNUT99 contains 4,500 foods and brand name pointers for most commercial 
foods and food analyses have been updated post mandatory fortification of 
breadmaking flour with thiamin (1991). It also has the facility for addition of food 
analyses, for foods not contained in the database, and thus ingredients of recipes, 
commercial foods etc were obtained and were hand converted by the dietitian into 
nutrients and added to the database.    
  
3.4.3 Thiamin supplementation 
 
Initial subjects 
Initial subjects supplied a 24-hour recall and any vitamin supplementation was 
recorded in this interview. Participants were classified as unsupplemented if they had 
not taken a thiamin supplement within the 10 days preceding the 24-hour recall. A 
standard form and a self addressed envelope were then given to participants for 
detailed information on type of supplement (name and manufacturer), dose, and 
when last supplement was taken prior to Diabetic Survey. This was followed up by 
phone to clarify any details, and also if the form was not returned within 2 weeks. On 
receipt of the form, further information was obtained on the amount of thiamin in the 
supplement. Information was obtained from the manufacturer; often from the 
company website, or by email. Supplement composition was either thiamin 
hydrochloride or thiamin nitrate. The proportion of thiamin was calculated using 
molecular weights: thiamin 266.4; thiamin hydrochloride 337.3; thiamin nitrate 
327.4; giving a proportion factor of 0.79 for thiamin in thiamin hydrochloride, and 
0.81 in thiamin nitrate supplements.  
Additional subjects 
Additional subjects did not supply a 24-hour recall but were sent a short 
questionnaire on supplement use  and requested to bring this when they came to 
Diabetic Survey (see appendix 5). Subjects were contacted by phone to clarify details 
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3.4.4 Diabetes control  HbA1c and hypoglycaemia 
 
Haemoglobin A1c 
This was assessed with cation exchange high pressure liquid chromatography, using  
BioRad Variant II, certified by the National Glycohaemoglobin Standardization 
Program (USA). With this method HbA1c elutes at a characteristic time and can be 
identified on a chromatogram (figure 3.1). Assessment of HbA1c has been discussed  
in 2.2.10.  
 
A)    B)     
  
Figure 3.2   Typical chromatogram A) normal, B) poorly controlled diabetes 
                     (Courtesy laboratory Royal Perth Hospital) 
 
Hypoglycemic episodes 
Average number of hypoglycaemic episodes per week was a standard additional 
question in the 24-hour recall interview as hypoglycemia with subsequent rebound 
can be a possible modifier of  HbA1c. The level at which a subject had symptomatic 
hypoglycaemia was used as a criterion, however there is obviously some variation in 
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3.4.5  Urinary albumin excretion 
 
Urinary albumin was collected from a fresh urine sample with no preservative 
required. Collection volume was 10  15 mL, analysed by  Immunoturbidimetric on 
Roche  Modular Autoanalyser. Normal range < 30 mg/L. 
 
3.4.6  Serum and red cell thiamin 
 
As discussed previously (2.1.20), there are several methods of biochemical 
assessment of thiamin status. The most common is an indirect method measuring 
change in erythrocyte transketolase activity with thiamin stimulation, but this is 
unsuitable for use in diabetes, as a documented increased content of  red cell 
membrane thiamin transporters probably falsely increases red cell content of thiamin 
at the expense of serum thiamin content thus elevating unstimulated transketolase 
activity.2 A more direct method of measurement is therefore required. 
 
The methodology used in this study was an automated microbiological assay of 
thiamin in serum and red cells by the method of  Icke and Nicol.9 This is a 
microbiological assay using Lactobacillus fermenti. Chloramphenicol and 
cycloheximide were added to suppress bacterial and yeast contamination. 
Spectrophotometric analysis was automated using a robotic liquid handling system. 
One serum sample was assayed 24 times in one batch to determine intrabatch 
precision, giving a coefficient of variation (CV) of  3-4%.  Three serum samples 
covering a wide range of values  were assayed 12 times in different batches over nine 
months to determine interbatch precision giving a CV for red cells of 7.4% and for 
serum of 6.1  10%. At the time of development the microbiological and an 
established thiochrome method were compared by assaying 10 red cell samples by 
both, and correlation was good (r = 0 99), although the microbiological assay gave 
results which were 21- 28% higher than the thiochrome method. Comparisons with 
serum thiamin concentrations were not carried out as  the thiochrome method used 
was not sensitive enough to measure serum, but the concentration of total thiamin 
found in the serum of healthy subjects by this method compared well with 
concentrations reported using sensitive HPLC methods.116 Non parametric reference 
ranges for both serum and red cell thiamin were determined on 505 healthy 
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individuals aged 18 to 90 years. None of these individuals were known to be 
currently receiving any therapy. Ranges were: serum thiamin 11.3-35.0 nmol/L (3.4 
 10.5 µg/L) and red cell thiamin 190-400 nmol/L (57.2  120.3 µg/L).  Results were 
not related to age or gender and the method was sensitive to 2.0 nmol/L of thiamin.9 
 
3.5   Data Analysis 
 
Statistical analysis was carried out using the Statistical Package for the Social 
Sciences (SPSS) version 13 for Windows. 
 
3.5.1  Validation of 24 hour recall 
 
Data was entered for the 31 subjects with repeat 24 hour recalls on a separate 
database. Variables entered were ID, first and repeat thiamin values, first and repeat 
carbohydrate values and first and repeat energy values (as calculated by 
Foodworks). 
 
Statistical testing was initially testing for normality, t-test for equality of means (age, 
duration of diabetes, BMI) and calculation of parametric and non parametric 
correlation coefficients between first and repeat values for each nutrient. A line of 
equality was drawn, and outliers identified. Means and differences for the initial and 
repeat values for thiamin, carbohydrate and energy were then calculated and recoded 
as new variables. A Bland Altman plot (means on the x-axis and differences on the 
y-axis) was generated, a mean of the differences (d) was calculated, 95% confidence 
intervals (d ± 1.96SD) was also calculated and all three lines entered on the graph. 
Standard error of both were ascertained. These were the limits of agreement and 
were compared to acceptable criteria for difference in these two nutrients.  
 
3.5.2 Initial subjects (89 total ) 
 
The database was split into two groups. type 1 and type 2 diabetes and baseline 
demographics examined for each group; weight, height, gender, age, duration of  
diabetes and diabetes treatment. Although groups were examined independently (not 
as comparison groups) t-tests were carried out for descriptive purposes. 
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Descriptive data including normality tests were then generated for the following 
continuous variables: dietary: dietary thiamin, supplementary thiamin, total thiamin 
intake, carbohydrate, mg thiamin per % carbohydrate, energy, mg thiamin per 1000 
kJ; indicators of diabetic control: HbA1c and average number of hypos; urinary 
albumin excretion and thiamin status: red cell and serum thiamin. 
 
Correlation coefficients ( Pearsons product moment correlation coefficient for data 
with a normal distribution and Spearmans nonparametric rank correlation 
coefficient) were generated to assess correlation with red cell and serum thiamin of 
dietary variables, indicators of diabetic control, age, BMI and duration of diabetes 
(for type 1 group only, as diagnosed duration of  diabetes is not accurate in type 2 
diabetes). 
 
To more accurately assess association, categorical variables were generated as 
follows: 
Thiamin intake: 
Adequate/Inadequate: Adequate thiamin intake was taken as  ≥ 1.1 mg/d for females 
and 1.2 mg/d for males and inadequate <  these levels. This was based on the current 
RDI values, which have a very generous margin for metabolic variation.40 The 
results of the National Nutrition Survey showed that 90% of Australians exceeded 
the RDI,82 and a study by Anderson196 showed that absolute daily thiamin 
requirement was more useful in predicting biochemical thiamin status than thiamin 
intake expressed as mg/1000 kJ. 
Thiamin per kJ 
Adequate thiamin per kJ/Inadequate thiamin per kJ: As there was literature 
supporting the requirement for thiamin being dependent on energy intake197 a 
categorical variable was generated based on this, as per previous RDI,40 with 
adequate ratio being  ≥ 0.0001 mg/kJ and inadequate < 0.0001 mg/kJ. 
Thiamin supplementation: 
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Age:  
Divided into tertiles, based on percentiles within the two groups: 
Type 1 Group: 
1. < 40 y 
2. 40  50 y 
3. 51  65 y 
4. > 65 y 
Type 2 Group 
1. < 56 y 
2. 56  61 y 
3. 62  68 y 
4. ≥ 69 y 
Duration (type 1 group only):  
a) Based on the earliest onset of problems with complications of diabetes167: 
1. < 5 y 
2. ≥ 5 y 
b) Based on tertiles: 
     1.  < 12 y 
     2.  12  22 y 
     3.  23  30 
     4.  > 30 
Body Mass Index: 
Based on values accepted internationally and for Australians198: 
1. < 20 (underweight) 
2. 20  25 (normal range) 
3. > 25  30 (overweight range) 
4. > 30 (obese) 
Haemoglobin A1c: 
Based on standardised values used for this test at this venue: 
1. < 6% - normal 
2. 6.1  7% - good glycemic control 
3. 7.1  8% - acceptable glycemic control 
4. > 8.1% -  poor glycemic control 
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Hypoglycemic episodes (type 1 group only): 
Based on greater and less than average number of hypoglycaemic episodes per week 
experienced by people with type 1 diabetes.199-201 
1. < 1.6 /week 
2. ≥ 1.6/week 
Urinary albumin 
Based on greater or less than the normal range for albumin excretion. 
1. < 30 mg/L 
2. ≥ 30 mg/L 
Red cell thiamin: 
Adequate/Inadequate based on standardised levels in microbiological 
assessment.9  
1. Adequate ≥ 190 nmol/L 
2. Inadequate < 190 nmol/L 
Serum thiamin: 
Adequate/Inadequate 
Adequate/Inadequate based on standardised levels in microbiological  
assessment.9  
1. Adequate ≥ 11.3 nmol/L 
2.   Inadequate < 11.3 nmol/L 
 
Statistical analysis using the χ2 test and Pearsons correlation was then carried out. 
 
3.5.3 Additional plus initial subjects (113 total) 
 
Grouping was by thiamin supplement, yes or no. Normality tests and t-test for 
equality of means were generated for continuous variables (age, BMI, HbA1c, 
urinary albumin excretion, duration of diabetes) and categorical variables were as 
above.  
Additional categorical variables generated were: 
Type of supplementation: 
Thiamin nitrate/thiamin hydrochloride 
When last supplement taken: 
Morning of survey/night before survey/ morning of day preceding survey  
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Thiamin status: 
Below normal range/within normal range/above normal range on standardised levels 
in microbiological assessment.9  
Serum thiamin within or above the normal range (11.3  35 nmol/L): 
1. < 11.3 nmol/L 
2. 11.3  35 nmol/L 
3. > 35 nmol/L 
Statistical analysis using the χ2 test and Pearsons correlation was carried out to 
determine relationship of supplementation to red cell and serum thiamin levels 
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CHAPTER 4       RESULTS 
 
4.1 Initial subjects - demographics  
 
There were 89 initial subjects, 44 with type 1 diabetes (27 male, 17 female) and 45  
with type 2 diabetes (23 males, 22 females). The intention was to analyze groups 
separately, rather than compare them. Initial subject demographics are shown in 
Table 4.1. Age, BMI and duration of diabetes were all normally distributed in type 1 
subjects (Shapiro-Wilk statistic 0.980, 0.950, 0.973; p = 0.635, 0.054, 0.372, 
respectively).  In type 2 subjects age and BMI were normally distributed (Shapiro-
Wilk statistic 0.986, 0.975; p= 0.860, 0.427) but duration of diabetes was not 
(Shapiro-Wilk statistic 0.940, p = 0.021). Data for duration of diabetes in type 2 is of 
limited value as diagnosis of onset of type 2 diabetes is notoriously unreliable, with 
many people remaining undiagnosed for prolonged periods. The Ausdiab study 
addressed prevalence of type 2 diabetes in Australia and showed one person 
undiagnosed for every person diagnosed.121 
 
 There was a large age range in both groups, with more variation in people with type 
1, as expected from a disease that is diagnosed in all age groups. Mean age was 
significantly higher in people with type 2 diabetes, which is largely diagnosed in 
older adults. Similarly mean years since diagnosis was significantly longer and 
varied more in type 1 subjects reflecting varied age at diagnosis, but shorter with less 
variation in type 2 subjects, who were, in the main, diagnosed at older ages (see 
Table 4.1). 
 
In 2007, 52% of people in the Australian population aged 15 years and over were 
classified as overweight or obese based on their calculated BMI.203 Compared to this, 
all subjects were more likely than the general population to be classified as 
overweight or obese, but type 1 subjects less so (type 1 59%, type 2 75.6% 
overweight or obese). There was similar variation in BMI in both groups but mean 
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Table 4.1  Initial subjects - characteristics 
 
Characteristic Type 1 diabetes Type 2 diabetes Significance (p) 
Age (y) 53.4 ± 14.8 62.0 ± 10.2  0.003 
Time since diagnosis 
(y) 
22.6  ± 11.7 12.6 ± 7.1 0.000 
BMI (kg/m2) 26.7 ± 4.4 31.2 ± 6.4  0.000 
 
 
Medications for diabetes treatment are shown in figure 4.1 and 4.2. As would be 
expected, all subjects with type 1 diabetes were on insulin, with the majority (75%) 
on a basal bolus regime of subcutaneous insulin with 4 or more injections a day. An 
additional 9.1% were on insulin pumps. The remainder were on less physiologically- 
based insulin regimes. Subjects with type 2 diabetes were on a wide variety of 
medication combinations, with the largest proportion being on the often used and 
simpler regimes, biguanide (17.8%), and double therapy (biguanide plus 
sulphonylurea). The small numbers on diet alone (8.9%) probably reflect exclusion 
criteria for the diabetic survey (< 1 year since diagnosis) and the population serviced 
by a specialist diabetic clinic. Increasing duration of type 2 diabetes, and referral for 
specialist attention signal increasingly more complicated diabetes with increased 
need for medication. Almost 20% of type 2 subjects had progressed to insulin 
regimes, with 6.6% on background insulin and 13.3% on multi insulin regimes. In all  
but 7.9%, insulin was accompanied by some sort of oral diabetes therapy. 















































































Figure 4.2  Diabetes treatment  subjects with type 2 diabetes 
 
 
4.2 Initial subjects - validation of 24-h recall 
 
Reproducibility of the 24-h recall was assessed by repeat 24-h recalls on 31 subjects 
( 34.8%) of the sample.  
 
4.2.1  Characteristics of repeat subjects 
 
Characteristics of repeat subjects versus subjects undergoing single 24-h recall and 
independent t-test on equality of means are shown in Table 4.2. 
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Table 4.2  Characteristics and t-test for equality of means for subjects undergoing 
                 single versus repeat 24-h recalls    
 
 
Characteristic Single recall Repeat recall Significance (p) 
Age (y) 57.2 ± 13.9 59.0 ± 12.6 0.55 
Time since  diagnosis (y) 18.6  ± 10.5 14.8 ± 11.5 0.12 
BMI (kg/m2) 28.2 ± 5.7 30.3  ± 6.1 0.12 
 
T-test for equality of means was carried out to determine equivalence of groups with 
respect to these characteristics. As Levenes test for equality of variance was not 
significant, equal variance was assumed. Mean age, duration of diabetes and BMI did 
not differ significantly between the two groups. Similarly, using cross tabulation and 
chi square for categorical variables there was no significant difference between the 
two groups in gender (p = 0.85), activity (p = 0.95) and smoking status (p = 0.125).  
The 31 subjects undergoing repeat recalls were assumed representative in these 
respects.  
 
4.2.2 Correlation of repeat and original 24-h recalls  
 
Reproducibility of  thiamin, carbohydrate and energy intakes were assessed by repeat 
24-h recalls. Normality testing was carried out and showed intake of carbohydrate 
was normally distributed in original and repeat recalls (Shapiro-Wilk statistic 0.949 
original carbohydrate and 0.952 repeat carbohydrate;  p = 0.168 and 0.211 
respectively), but thiamin and energy intake were not (Shapiro-Wilk statistic 0.767 
and 0.831 for original and repeat thiamin, respectively, and 0.805 and 0.908 for 
original and repeat energy, respectively; p < 0.01. Parametric and nonparametric 
testing were carried out for thiamin and carbohydrate as sample size > 30, however 
only nonparametric testing was carried out for energy (non-normal distribution, 
sample size < 30). 
Thiamin  
Mean original thiamin intake was 1.22 ± 0.55 mg, mean repeat 1.33 ± 0.69 mg. 
Correlation of original and repeat thiamin intake was good, with Pearsons product 
moment correlation coefficient (r) of 0.861 and Spearmans nonparametric rank 
correlation coefficient (rs) of  0.770, both significant at the 0.01 level.  
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Carbohydrate 
Mean original carbohydrate intake was 156.88 ± 65.34 g, mean repeat 162.85 ± 
69.64 g. Correlation of original and repeat carbohydrate intake was good with r of  
0.567 and rs  of  0.629, both significant at the 0.01 level.  
Energy 
Mean original energy intake was 6387 ± 2558 kJ, and mean repeat 6497 ± 2460 kJ. 
Correlation of original and repeat energy intake was good with rs  of  0.608, 
significant at the 0.01 level.  
 
 
4.2.3 Repeatability as assessed by Bland Altman plot. 
 
Thiamin 
Initially, a scatterplot of original and repeat thiamin values was generated with the 
line of equality plotted (figure 4.3). There was clustering around the line of equality 
but also several outliers. A Bland Altman plot was then generated (figure 4.4). Mean 
of differences (0.112 ± 0.35)  was calculated. This was the bias (standard error - 
0.002) with the limits of agreement (95% confidence limits) being 0.8054 and -
0.5812 (standard error - 0.0035). Variability was consistent across the graph, with no 
increasing or decreasing trend in variability with increasing mean. The interpretation 
of this was that we can be confident that 95% of the time the value of thiamin intake 
as assessed by repeat 24-hour recalls will be within 0.6 mg of the original estimate 
across the range of measurement. This was 46% of mean thiamin intake so was 































Figure 4.3  Correlation of thiamin intake with line of equality 
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Figure 4.4  Bland Altman plot  thiamin 
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Carbohydrate 
Initially, a scatterplot of original and repeat carbohydrate values was generated with 
the line of equality plotted (figure 4.5). There was reasonable clustering around the 
line of equality but more outliers than for the thiamin plot. A Bland Altman plot was 
then generated (figure 4.6). The bias was 5.97 (standard error  11.30) with the limits 
of agreement being 129.30 and -117.3 (standard error  19.57). Variability was 
consistent across the graph, with a slight trend towards increasing variability of 
difference with increasing mean. The interpretation was that we can be confident that 
95% of the time the value of carbohydrate intake as assessed by repeat 24-hour 
recalls will be within 123.3 g of the original estimate with possibly larger variation at 
higher levels of carbohydrate intake. The agreement between original and repeat 
carbohydrate values was much less than for thiamin values, and variability increased 
with increasing carbohydrate intake. Correlation coefficient was good but a limit of 
agreement of 123.3 is substantial, and suggests that assessed carbohydrate values, 
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Figure 4.6  Bland Altman plot  carbohydrate 
 
Energy 
Initially, a scatterplot of original and repeat energy values was generated with the 
line of equality plotted (figure 4.7). Clustering around the line of equality was good, 
with only one obvious outlier. A Bland Altman plot was then generated (figure 4.8). 
The bias was 38.2014 (standard error  433.04) with the limits of agreement being 
4609 and -4533 (standard error  750.05). With the exception of one outlier, 
variability was quite consistent across the graph. The bias was relatively small so 
there appeared little systematic error in energy estimation, and the consistent 
variability supported this, however the limits of agreement were relatively large. This 













































Figure 4.8  Bland Altman plot  energy 
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4.3 Initial subjects - dietary intake profiles 
 
4.3.1  Initial subjects - dietary thiamin 
 
Dietary thiamin had the greatest reproducibility on repeat recall among the nutrients 
studied. It had a  non normal distribution in both groups (Shapiro-Wilk statistic 0.782 
and 0.789, p = .000). In initial subjects, people with type 1 diabetes had a median 
thiamin intake of 1.43 mg, and those with type 2 diabetes, a median intake 1.11 mg. 
As the RDI for thiamin is gender specific, thiamin intake of initial subjects according 
to both diabetes type and gender was considered ( Table 4.3). 
  




Type 1 Type 2 








































In both types of diabetes males had a higher median intake of thiamin than females, 
consistent with the trend noted in the 1995 National Nutrition Survey that males 
consumed larger quantities of vitamins and minerals than females82. With the 
exception of females with type 2 diabetes, median thiamin intake in all groups was ≥ 
than the RDI (1.2 mg M, 1.1 mg F). In females with type 2 diabetes 87.6% (78 
subjects) had a dietary thiamin intake above the RDI. 
  
4.3.2  Initial subjects - energy intake 
 
Energy intake was normally distributed in type 1 subjects  (Shapiro-Wilk statistic 
0.976, p = 0.495) but not in type 2 (Shapiro-Wilk statistic 0.858, p = .000), possibly 
reflecting a skew in energy intake in a group with a mean BMI in the overweight 
range. Subjects with type 1 diabetes had a mean energy intake of  6273 ± 1900 kJ. 
Mean energy intake was less in those with type 2 diabetes being 6020 ±2702 kJ. 
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Looking at energy intake according to gender, as well as type of diabetes (see Table 
4.4), all males had a significantly higher mean energy intakes than females (p = 
0.000) (as expected).  
 
4.3.3  Initial subjects - thiamin intake per 1000 kJ 
 
Until the 2005 revision of NRVs the RDI for thiamin was expressed per energy 
value204 (see section 2.1.15) and thiamin intake is shown expressed thus in Table 4.4. 
This shows a slightly different pattern of intake, with total mean mg thiamin per 
1000 kJ being greater in type 1 than in type 2 subjects, but males with type 2 having 
a smaller mean ratio than type 2 females, possibly due to a higher mean energy 
intake without a concomitantly increased thiamin intake (Table 4.4). By assessing 
adequacy of intake in this form, taking 0.1 mg per 1000kJ as adequate, it can be 
easily seen that mean intake was highly adequate in all groups. 
   
4.3.4  Initial subjects - carbohydrate intake 
 
Carbohydrate intake similarly had a normal distribution in type 1 subjects (Shapiro- 
Wilk statistic 0.963, p = 0.169) and non normal in type 2 subjects ((Shapiro-Wilk 
statistic 0.900, p = 0.001). Subjects with type 1 diabetes had a higher mean 
carbohydrate intake (166.49 ± 63.82 g) compared to those with type 2 diabetes, 
(149.76 ± 61.24 g). Males in both groups had a significantly higher mean 
carbohydrate than females (p = 0.000) (Table 4.4). Carbohydrate as a percentage of 
energy intake was unremarkable, with mean percent intake varying little between 
groups (Table 4.4), and standard deviation being a little greater in type 2 than type 1 
subjects. 
 
4.3.5  Initial subjects - thiamin intake per % carbohydrate 
 
Mean thiamin intake per percent of carbohydrate (Table 4.4) was the converse of  the 
pattern of mean thiamin intake, with all subjects with type 2 diabetes having higher 
mean intakes per percent carbohydrate than those with type 1, and males having a 
lower intake than females in each group. 
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Table 4.4  Initial subjects  dietary thiamin proportional to energy and  
                 carbohydrate intake  
    
Diabetes Type 1 Type 2 
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1.16 ±  
2.35 
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4.3.6  Initial subjects - supplementary thiamin 
 
Of the 89 initial subjects, 19 were taking thiamin-containing supplements. Subjects 
taking thiamin-containing supplements were evenly distributed between groups and 
gender, with 9 (4 female, 5 male) having type 1 diabetes and 10 (6 female, 4 male) 
having type 2 diabetes. Supplements consisted of either thiamin hydrochloride (10), 
or thiamin nitrate (9) and were taken on survey morning (1) or the morning of the 
day preceding survey (6) with 12 not able to supply this information. Mean thiamin 
content of supplements was 19.87 ± 15.25  mg. The greatest content was 59.25 mg, 
giving that subject a total thiamin intake of 60.28 mg. The least was 2.43 mg giving a 
total thiamin intake of 4.01 mg. Total thiamin intake of all supplemented subjects 
exceeded 4 mg, almost 4 times the RDI.  
 
4.4 Initial subjects - other possible modifiers of thiamin status 
 
Activity and smoking were reported as categorical variables. Indices of control and 
complications were continuous variables. 
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4.4.1 Initial subjects - level of activity 
 
Level of activity was self reported, as sedentary, moderate and heavy and 
frequencies of each level are shown in Table 4.5. 
 
Table 4.5   Initial subjects - level of activity 
 
Diabetes type Activity level Frequency Percent 
Sedentary 14 31.8 
Moderate 21 47.7 
Heavy 9 20.5 
Type 1 (n = 44) 
Total 44 100.0 
Sedentary 23 51.1 
Moderate 22 48.9 
Type 2 (n = 45) 
Total 45 100.0 
 
 
 Level of activity is, as might be expected, higher in the younger, leaner type 1 
subjects, with 68.2% reporting higher than sedentary activity compared to the type 2 
groups 48.9%. No type 2 subject reported heavy activity, versus 20.5% in type 1 
subjects. 
 
4.4.2  Initial subjects - smoking status 
 
Only present smoking status was assessed, with both groups being distinguished by a 
paucity of smokers. Only 13.6% (6) of type 1 subjects and 8.9% (4) type 2 subjects 
were smokers. 
 
4.4.3  Initial subjects - diabetes control and complications 
 
Haemoglobin A1c 
Haemoglobin A1c levels were based on standardised values used for this test at this 
venue which are: 
< 6% - normal 
6.1  7% - good glycemic control 
7.1  8% - acceptable glycemic control 
> 8.1% -  poor glycemic control 
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HbA1c had a normal distribution in both groups (Shapiro-Wilk statistic 0.980, 0.981 
p = 0.621, 0.675). Mean HbA1c  was 7.8% in both groups (type 1 - 7.87 ± 1.38%; 
type 2 - 7.84 ± 1.55%), which is in the acceptable only range. There was a large 
standard deviation, especially in the type 2 subjects, with maxima in both groups 
well into the poor glycemic control range (type 1 - 10.80%; type 2 - 11.40%) . 
Frequency of symptomatic hypoglycaemia (hypos) 
Hypoglycemia is a feature of type 1 diabetes, but rarely a problem in type 2. As 
discussed previously (section 2.2.10), episodes of hypoglycaemia modify HbA1c, 
which is essentially an average, and this may result in the appearance of good 
control, as assessed by HbA1c, in the presence of fluctuating blood glucose levels. 
Symptomatic hypoglycaemia (hypos) which are usually recognised, and often 
recorded by people with type 1 diabetes are an indicator of the frequency of 
hypoglycaemia. Mean number of self reported hypos in type 1 subjects was 1.5 per 
week, with a large variation, with some subjects reporting no hypos and others 
almost one a day.  
Urinary albumin 
Normal range for urinary albumin at this venue was  < 3.0 mg/L. Urinary albumin 
had a non normal distribution in initial subjects with Shapiro-Wilk statistic 0.431 and 
0.383 with p = 0.000. Data on urinary albumin excretion was available for only 28 
(total 44) type 1 subjects and 37 (total 45) type 2 subjects. Median value of urinary 
albumin was slightly above the normal range in type 1 subjects (3.0 mg/L) and more 
markedly above in type 2 subjects (5.3 mg/L). Minimum values (2 mg/L) were the 
same in both groups. Maximum values were 41.5 mg/L in type 1 and 208 mg/L in 
type 2 subjects. 
 
4.5 Initial subjects - markers of thiamin status 
 
4.5.1  Initial subjects - serum thiamin 
 
Serum thiamin had a non-normal distribution in both groups (Shapiro-Wilk statistic 
0.886, 0.849; p =0.000). Median serum thiamin was within the normal range (11.3  
35 nmol/L) for initial subjects, but lower among unsupplemented subjects (Table 
4.6). Median values were lowest in unsupplemented type 2 subjects and highest in 
type 1 subjects when supplemented subjects were included; type 2 subjects had a 
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slightly higher rate of supplementation. Minimum values were below, or just reached 
the lower level of the normal range for serum thiamin. 
 
Table 4.6   Initial subjects - serum thiamin 
 
Subjects Diabetes type Median serum thiamin (nmol/L) 
[range] 
Type 1 (44) 19.1 [11.4  50.9] All initial subjects 
     (89) Type 2 (45) 18.1 [9.8  52.0] 
Type 1 (35) 18.4 [11.4  30.5] Unsupplemented initial 
subjects   (70) Type 2 (35) 16.5 [9.8  43.5] 
 
 
4.5.2  Initial subjects - red cell  thiamin 
 
Red cell thiamin had a normal distribution in both groups (Shapiro-Wilk statistic 
0.979, 0.980; p = 0.594, 0.605). Mean red cell thiamin levels were lower in all 
unsupplemented subjects than the whole group (Table 4.7). Minimum values in all 
groups were below the normal range, with unsupplemented type 1 subjects having 
the lowest mean. 
 
Table 4.7   Initial subjects - red cell  thiamin 
 
 
Subjects Diabetes type Mean red cell thiamin 
(nmol/L) [range] 
Type 1 (44) 251.5 ± 59.1 [142.0  398.0] All initial subjects 
     (89) Type 2 (45) 276.8  ± 72.2 [139.0  450.0] 
Type 1 (35) 244.9  ± 61.4 [142.0  398.0] Unsupplemented initial 
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4.6 Initial subjects  preliminary correlations using continuous variables 
 
Continuous variable correlations  were carried out as a preliminary investigation. 
  
4.6.1  Correlations with serum thiamin 
 
Looking at possible minor modifiers of thiamin status, there was no correlation 
between serum thiamin and BMI, HbA1c, HbA1c controlled for hypoglycaemic 
episodes, or urinary albumin. Serum thiamin correlated with age in subjects with 
type 2 diabetes but not in type 1; it also correlated with duration in type 1 diabetes 
(all p < 0.05) (see Table 4.8). An attempt to assess correlation of serum thiamin with 
duration was not carried out in type 2 subjects due to the difficulty of assessing 
duration in type 2 diabetes. For dietary variables, there was no correlation between 
serum thiamin and carbohydrate, energy, % of energy as carbohydrate, thiamin per 
1000 kJ or thiamin per % carbohydrate. There was also no correlation between serum 
thiamin and total thiamin intake in unsupplemented subjects (Table 4.8), but there 
was a correlation (p < 0.05) in type 2 subjects when supplemented subjects were 
included.  
 
Table 4.8   Initial subjects  correlations, serum thiamin and possible modifiers   
  








Variable Subjects  r p r p  




Whole group 1 0.343 0.023 0.325 0.031 p < 0.05 
1 - - - - n.s Unsupplemented





Whole group 2 0.619 0.000 0.369 0.013 p < 0.05 
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3.0002.0001.0000.000



































Figure 4.9   Initial subjects - scatterplot, serum thiamin versus total thiamin intake 
                    in  type 2 subjects  a) unsupplemented,  b) whole group  
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Figure 4.10   Initial subjects - scatterplot, serum thiamin versus total thiamin intake 
                    in  type 1 subjects  a) unsupplemented,  b) whole group  
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4.6.2 Correlations with red cell thiamin 
 
Correlations with red cell thiamin were similar to those of serum thiamin (Table 4.9), 
with all minor modifiers failing to correlate except for a correlation with age ( p < 
0.05) in type 2 subjects only. There was a correlation (parametric only) between total 
thiamin intake and red cell thiamin in type 2 subjects (including supplemented), 
however total thiamin intake had a non normal distribution so this was discounted.  
 
Table 4.9   Initial subjects - correlations, red cell  thiamin and possible modifiers                     
 










Variable Subjects  r p r p  
Age (y) Whole group 2 0.387 0.009 0.411 0.005 p  < 0.05 
1 - - - - n.s Without 





Whole group 2  0.315 0.035 - - p  < 0.05 
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3.0002.0001.0000.000




































Figure 4.11   Initial subjects - scatterplot, red cell thiamin versus total thiamin intake 
                    in  type 2 subjects  a) unsupplemented,  b) whole group  









































Figure 4.12   Initial subjects - scatterplot, red cell thiamin versus total thiamin intake 
                    in  type 1 subjects  a) unsupplemented,  b) whole group  
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4.6.3   Correlation red cell versus serum thiamin 
 
There was a consistent strong correlation between red cell and serum thiamin on both 
parametric and nonparametric testing. Non parametric testing was the strongest 
indicator in view of the non normal distribution of serum thiamin, and was valid at 
the level p < 0.01. 
 
Table 4.10   Initial subjects  correlation - red cell  thiamin and serum thiamin  
 









 r p r p  
























R Sq Linear = 0.215
 
 
Figure 4.13  Initial subjects - Scatterplot, red cell thiamin versus serum thiamin  
                     (Equation: RCT = 3.47ST + 191.67) 
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4.7   Initial subjects  nonparametric testing using the χ2 test 
 
Categorical variables were generated as described in section 3.4.2. Dietary variables, 
and other possible modifiers were tested for association with attainment of red cell 
thiamin and serum thiamin within the normal range using cross tabs and Pearsons 
chi square. 
 
4.7.1  Initial subjects  association of serum and red cell thiamin 
 
There was a consistent association between attainment of red cell thiamin within the 
normal range and attainment of serum thiamin within the normal range, with 33.3% 
(1)  of subjects with serum thiamin below the normal range attaining red cell thiamin 
within the normal range, versus 89.5% (77) of subjects with serum thiamin within or 
above the normal range  (p = 0.039).  
 
 
4.7.2 Initial subjects  dietary variables versus thiamin status 
 
Dietary variables were assessed for all initial subjects  and then separately  in those 
without thiamin supplementation. It was not possible to carry out Pearsons chi 
square on the supplemented group as there were too few subjects. There was no 
association between attainment of red cell thiamin within the normal range and 
thiamin intake or thiamin per 1000kJ in either group (type 1 and type 2) in all initial 
subjects or unsupplemented subjects alone. Similarly there was no association 
between attainment of serum thiamin within the normal range and the same 
variables. 
 
4.7.3  Initial subjects non-dietary variables versus thiamin status 
 
There was no association in either group (type 1 and type 2) between attainment of 
red cell thiamin within the normal range and gender, age, BMI, HbA1c (categorised 
by both probability of complications and also tertiles; see section 3.4.2), frequency of 
hypoglycaemia, urinary albumin excretion, smoking status, activity and duration of 
diabetes (type 1 only). Similarly there was no association between attainment of 
serum thiamin within the normal range and the same variables. 





































Figure 4.14   Initial subjects - Scatterplot, red cell thiamin versus HbA1c 
                    a) unsupplemented,  b) whole group  
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4.8 Initial subjects - trends in thiamin status in supplemented subjects 
 
The number of supplemented subjects was insufficient for statistical analysis by 
Pearsons chi square, therefore, frequency counts were carried out to see if there was 
a trend toward or away from attaining adequate thiamin status. 
 
4.8.1  Initial subjects - serum thiamin  
 
The frequency of subjects attaining serum thiamin within the normal range (11.3  
35 nmol/L) was delineated comparing supplemented and unsupplemented subjects. 
In subjects with type 1 diabetes, 35 were unsupplemented and 9 supplemented. Data 
for serum thiamin showed 0% of supplemented and unsupplemented type 1 subjects 
failed to attain serum thiamin within the normal range. In subjects with type 2 
diabetes 35 were unsupplemented and 10 supplemented. In type 2 subjects 8.6% (3) 
unsupplemented and 0% of supplemented subjects failed to attain serum thiamin 
within the normal range.  
 
4.8.2  Initial subjects  red cell thiamin  
 
Similarly numbers of supplemented subjects were insufficient for statistical analysis 
by Pearsons chi square for attainment of red cell thiamin within the normal range 
(190  400 nmol/L). Frequency of subjects attaining red cell thiamin within the 
normal range was delineated comparing supplemented and unsupplemented subjects 
in type 1 and type 2 diabetes. In subjects with type 1 diabetes, 35 were 
unsupplemented and 9 supplemented. Of those unsupplemented 17.1% (6) failed to 
attain red cell thiamin within the normal range, whereas in the supplemented group 
0% failed to attain red cell thiamin within the normal range. Similarly in subjects 
with type 2 diabetes 35 were unsupplemented and 10 supplemented. A total of 14.3% 
(5) of type 2 subjects failed to attain red cell thiamin within the normal range, 
whereas 0% of supplemented subjects failed to attain red cell thiamin within the 
normal range.  
 
The small numbers of supplemented subjects precluded testing to significance, 
however, although in initial subjects a dietary intake above the RDI was not 
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associated with attainment of red cell thiamin within the normal range, there was a 
trend that supplementation might be. 
 
4.9  Summary 
 
There were 89 initial subjects, 44 with type 1 diabetes (27 male, 17 female) and 45  
with type 2 diabetes (23 males, 22 females) with 70 taking diet alone and 19 taking 
thiamin-containing supplements ( 9 [4 female, 5 male] having type 1 diabetes and 10 
[6 female, 4 male] having type 2 diabetes). 
 
Using chi square and Pearsons correlation: 
• There was no association in either group (type 1 and type 2) between 
attainment of serum and red cell thiamin within the normal range and gender, 
age, BMI, HbA1c frequency of hypoglycaemia, urinary albumin excretion, 
smoking status, activity and duration of diabetes (type 1 only). 
• There was a consistent significant correlation between red cell and serum 
thiamin on both parametric and nonparametric testing. Non parametric 
testing was the strongest indicator in view of the non normal distribution of 
serum thiamin, and was valid at the level p < 0.01. 
• There was no association between attainment of serum and red cell thiamin 
within the normal range and thiamin intake or thiamin per 1000kJ in either 
group (type 1 and type 2) in all initial subjects or unsupplemented subjects 
alone.  
• The number of supplemented subjects was insufficient for statistical analysis 
by Pearsons chi square. However in the 19 subjects taking supplements,  all 
attained serum and red cell thiamin levels within the normal range.  
 
4.10  Extension of study  additional subjects 
 
Additional subjects (24) on supplementation were recruited to ensure sufficient 
numbers for statistical testing comparing supplemented and unsupplemented subjects 
(see section 3.3.1). This section of the study aimed to investigate the effect of 
thiamin supplementation per se on thiamin status, therefore a 24h-recall was 
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considered unnecessary. This gave a total of 113 subjects (58 type 1 and 55 type 2) 
with 43 supplemented and 70 unsupplemented. 
 
In the initial subjects, there had been little significant difference in correlations 
between dietary and non dietary variables and markers of thiamin status between the 
type 1 and type 2 diabetes groups. In addition, testing using the χ2 test and Pearsons 
correlation showed no significant difference in distribution of subjects with type 1 
and type 2 diabetes between the supplemented (53.5% [23] type 1 and 46.5% [20] 
type 2) and unsupplemented groups 50% [35] type 1 and 50% [35] type 2) (p = 
0.847).  Therefore both type of diabetes were analysed together in this section. 
 
4.10.1  Descriptive data   supplemented and unsupplemented group  dietary 
 
Distribution of total thiamin intake was non-normal in the unsupplemented group 
(Shapiro-Wilk statistic 0.704, p = 0.000). In the supplemented group total thiamin 
intake could only be determined for the 19 initial supplemented subjects (who had 
dietary intake assessed by 24-h recall), but not for the 24 additional subjects. 
Distribution of thiamin content of supplements was nonnormal (Shapiro-Wilk 
statistic 0.704, p = 0.000). In the supplemented group, 25 subjects were 
supplemented with thiamin nitrate and 18 with thiamin hydrochloride. Of these, 7% 
(n = 3) took last supplement on survey morning, 4.7% (n = 2) the night before, 
51.2% (n = 22) the morning of the day preceding survey and 37.2% (n = 16) did not 
remember. Median total thiamin intake was 1.1 mg in the unsupplemented group 
(equivalent to the RDI for women), with minimum intake 0.37 mg and maximum 
4.44 mg. Variation in thiamin content of supplements was large, giving great 
variability in thiamin intake in the supplemented group. The minimum total intake in 
this group was 4.01 mg in an initial supplemented subject, which is almost four times 
the RDI. The maximum was 122.60 mg plus dietary intake in an additional subject. 
This is over 100 times the RDI. 
 
4.10.2 Supplemented and unsupplemented  groups  other  thiamin modifiers             
 
Basic demographic variables (age and BMI) and possible modifiers of thiamin status 
(HbA1c and urinary albumin excretion) was similar between the groups in both mean 
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values and variation. Duration was assessed in subjects with type 1 diabetes only and 
was similar between groups, in both mean values and variation. Independent samples 
t-test was carried out on these continuous variables to determine the equivalence of 
the supplemented and unsupplemented groups in these respects. Variances were 
assumed equal for BMI, HbA1c, duration in type 1s and urinary albumin excretion 
as Levenes test for equality of variances did not reach significance. Equal variance 
was not assumed for age (Levenes test for equality of variances, p = .011). T-test for 
equality of means did not reach significance, and the groups were presumed 
equivalent with respect to basic demographics and possible thiamin status modifiers 
HbA1c and urinary albumin excretion.  
 
Table 4.11  Supplemented and unsupplemented groups  comparison of 
                      demographics and minor modifiers - independent t-test 
 
Variable Group Mean Significance (p) 
Unsupplemented 58.5 ± 13.0 Age (y) 
Supplemented 56.0 ± 15.9 
0.390 
Unsupplemented 28.7 ± 6.0 BMI (kg/cm2) 
Supplemented 28.9 ± 5.3 
0.900 
Unsupplemented 7.9 ± 1.5 HbA1c (%) 
Supplemented 7.8 ± 1.4 
0.720 
Unsupplemented 13.9 ± 35.9 Urinary albumin (mg/l) 
Supplemented 11.0 ± 28.0 
0.680 
Unsupplemented 23.1 ± 11.5 Duration diabetes (y) 
(Type 1 subjects only) Supplemented 26.6 ± 15.0 
0.101 
 
Equivalence of self reported categorical variables, smoking status and activity level 
between the supplemented and unsupplemented groups was tested by statistical 
analysis using the χ2 test and Pearsons correlation. Smoking status was expressed as 
smoker or nonsmoker, and there was no significant difference between the 
supplemented and the unsupplemented groups in smoking status with 88.6% (62) of 
supplemented subjects and 93% (40) of unsupplemented subjects being nonsmokers 
(p = 0.528).  
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Activity level was expressed as sedentary, moderate or heavy (see Table 4.12). 
Statistical testing using the χ2 test and Pearsons correlation showed no significant 
difference between the supplemented and unsupplemented groups in activity levels 
(p = 0.468).  
Table 4.12    Supplemented versus unsupplemented groups  activity level 
 
Activity level  
Group Sedentary Moderate Heavy 
 
Total 
Unsupplemented 41.4% (29) 47.1% (33) 11.4% (8) 100% (70) 
Supplemented 44.2% (19) 51.2% (22) 4.7% (2) 100% (43) 
 
 
In summary, there was no significant difference between the supplemented and 
unsupplemented groups in type of diabetes, age, BMI, HbA1c, urinary albumin 
excretion, duration of diabetes in type 1 subjects, smoking status and activity levels. 
 
 
4.10.3  Supplemented (n = 43) and unsupplemented (n = 70)  groups  markers of 
            thiamin status 
 
Serum thiamin 
Median, minimum and maximum values of serum thiamin were markedly higher in 
the supplemented group than the unsupplemented. All values were above the normal 
range in the supplemented group, with the maximum value in the supplemented 
group being approximately three times the upper level of the normal range. The 
range of values was also greatly increased in the supplemented group (see Table 
4.13). 
Table 4.13  Supplemented and unsupplemented groups  serum thiamin   
                    descriptives 
 
 
Serum thiamin (nmol/L)  
Group Median Minimum Maximum 
 Unsupplemented (70) 17.35 9.80 43.50 





  - 100 - 
 
Red cell thiamin 
All values of red cell thiamin were markedly higher in the supplemented group than 
in the unsupplemented group, with over twice the standard deviation (see Table 
4.14). 
 
Table 4.14  Supplemented and unsupplemented groups  red cell thiamin   
                    descriptives. 
 
 
Red cell thiamin (nmol/L)  
Group Mean Minimum Maximum 
 Unsupplemented (70) 253. 97 ± 64.63 139.00 398.00 




4.10.4  Supplemented and unsupplemented  groups  dietary thiamin intake- 
            correlations and attainment of adequate thiamin status. 
  
Serum thiamin 
Preliminary correlation with continuous variables showed no correlation between 
total thiamin intake and serum thiamin in the unsupplemented group ( r = 0.098, p = 
0.4180) but a strong correlation between total thiamin intake and serum thiamin in 
the supplemented group ( r = 0.591, p = 0.000). 
 
Categorical variables were as described in section 3.4.2. Total thiamin intake was 
tested for association with attainment of serum thiamin within the normal range. 
Categorical variables used were < 11.3 nmol/L and ≥ 11.3 nmol/L (the lower limit of 
the normal range for serum thiamin). Using cross-tabulation, and testing with 
Pearsons chi square, the likelihood of attaining an adequate level of serum thiamin 
was not significantly different between the  supplemented and unsupplemented 
groups (p = 0.287). 
 
Three categorical variable were then used; categorising serum thiamin as below (< 
11.3 nmol/L), within (11.3  35 nmol/L) and above (> 35 nmol/L) the normal range.  
Distribution within these categories can be seen in table 4.15. In the unsupplemented 
group 4.3% of subjects were below the normal range, but the majority of subjects 
(91.4%) were within the normal range, with only 4.3% above the normal range, 
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whereas in the supplemented group, no subject was below the normal range and  
44.2%  of subjects were above the normal range. Type of supplement (thiamin 
hydrochloride or thiamin nitrate) was not significantly associated with level of serum 
thiamin (p = 0.60). Levels of serum thiamin in subjects who had last supplemented ≥ 
24 hours previously were  almost identically distributed (0% below normal range, 
54.5% within normal range and 45.5% above normal range).  
 
Table 4.15    Supplemented versus unsupplemented groups  distribution of serum 
                       thiamin  
 
Serum thiamin  
Group Below normal range 
(< 11.3 nmol/L) 
Within normal range 
(11.3  35 nmol/L) 
Above normal range 
(> 35 nmol/L) 
Unsupplemented 
(70) 
4.3% (3) 91.4% (64) 4.3% (3) 
Supplemented 
(43) 
0.0% (0) 55.8% (24) 44.2% (19) 
 
 
Using cross-tabulations and Pearsons chi square there was a significant association 
between thiamin supplementation and having a serum thiamin above the normal 
range in all unsupplemented subjects (p = 0.00) and a similar significant association 
between thiamin supplementation ≥ 24 hours previously and having a serum thiamin 
above the normal range (p = 0.00).  
Red cell thiamin 
Preliminary correlation with continuous variables showed no correlation between 
total thiamin intake and red cell thiamin in either the unsupplemented group ( r = - 
0.025, p = 0.839) or the supplemented group ( r = 0.066, p = 0.674). It can be seen 
however, that a much lower percentage of supplemented subjects than 
unsupplemented had red cell thiamin levels below the normal range ( (Table 4.16) 
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Table 4.16   Supplemented versus unsupplemented groups  distribution of red cell 
                    thiamin. 
 
Red cell thiamin  
Group Below normal range  
(< 190 nmol/L) 
Within or above normal 
range (≥ 190 nmol/L) 
Unsupplemented (70) 15.7% (11) 84.3% (59) 
Supplemented (43) 2.3% (1) 97.7% (42) 
 
Using cross-tabulations and Pearsons chi square there was a significant association 
between thiamin supplementation and having a red cell thiamin within the normal 
range (p = 0.028).  
 
4.11  Summary 
 
In the initial subject group (n = 89, 70 unsupplemented, 19 supplemented): 
• There was a consistent strong association between serum and red cell thiamin 
on both continuous and categorical testing using Pearsons chi square. 
• There was an initial correlation between age, total thiamin intake and serum 
thiamin in type 2 subjects, and duration and serum thiamin in type 1 subjects 
but this was not supported on categorical testing using Pearsons chi square. 
There was an initial correlation between age, total thiamin intake and red cell 
thiamin in type 2 subjects, similarly unsupported by categorical testing using 
Pearsons chi square. 
• There was a strong trend toward supplemented subjects attaining a red cell 
thiamin within the normal range but subject numbers precluded testing to 
significance.  
• There was no significant association between indicators of diabetes control 
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In the total group (initial plus additional subjects n = 113, 70 unsupplemented, 43 
supplemented): 
• There was a consistent, highly significant association between serum and red 
cell thiamin on both continuous and categorical testing using Pearsons chi 
square. 
• Using continuous variables, there was a correlation between total thiamin 
intake and serum thiamin in the supplemented group but not in the 
unsupplemented group. 
• Using categorical variables and Pearsons chi square there was a strong 
association between being supplemented and having a serum thiamin above 
the normal range. 
• Of subjects who had taken last supplement on the morning of the day 
preceding survey, 45% had elevated serum thiamin levels 24 hours later. 
• Using categorical variables and Pearsons chi square there was a strong 
association between being supplemented and having a red cell thiamin within 
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CHAPTER 5:   DISCUSSION 
 
5.1 Reduced thiamin status 
 
The study aim was to investigate the relationship between thiamin  intake, diabetes 
control and thiamin status in people with diabetes in Perth, Australia. Subjects were 
113 people with diabetes (58 type 1, 55 type 2). The study showed reduced thiamin 
status in subjects with type 1 and type 2 diabetes, with 15.7 % (n = 11) of 
unsupplemented subjects having a red cell thiamin below the normal range. Serum 
thiamin levels were less reduced, with 3.4% (n = 3) unsupplemented subjects having 
serum thiamin below the normal range. There is not an enormous number of studies 
on this topic in the literature but most record some sort of reduction in thiamin status 
in diabetes. Comparisons can be difficult as studies variously report results for whole 
blood, plasma, but rarely red cell thiamin levels. (The concentration of thiamin in red 
blood cells is approximately 12 times that in plasma so whole blood is the nearest 
approximation to red cell levels). This study is essentially concordant with studies by 
Hobara, Kodentsova and Saito, who documented reduced thiamin levels in whole 
blood.3, 169, 170, 172 Haugen also showed low levels of thiamin in whole blood in type 1 
diabetes (but normal levels in type 2 diabetes).175 This study differs from studies by 
Tamai and Havivi who reported decreased plasma thiamin levels in diabetes,4, 171 and  
also Thornalley, who reported plasma thiamin concentrations decreased 76% in type 
1 diabetes and 75% in type 2 diabetes compared with people without diabetes. 
Conversely there are reports of normal blood thiamin levels in diabetes in both 
humans,5, 173 and also in animal studies.174  
 
Compounding the difficulties in making comparisons between this study and others 
is the differing methodology used in assessment of thiamin status in different 
laboratories.  Hobara used a microbiological method of assessment using 
Lactobacillus viridescence.170 Kodentsova  measured transketolase activity172 and 
Saito and Haugen used a  fluorometric thiochrome method.3, 175 More recent studies, 
for example that by Thornalley have assessed thiamin levels in plasma and red blood 
cells using high performance liquid chromatography.2 The thiamin assessment used 
in the present study was an automated microbiological assay of serum and red cell 
thiamin using Lactobacillus fermenti by the method of  Icke and Nicol.9 These 
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authors standardised their method against an established thiochrome method, with 
good correlation (r = 0.99), but the microbiological assay gave results which were 
21- 28%  higher than the thiochrome method. Comparisons with serum thiamin 
concentrations were not carried out in this way as  the thiochrome method used was 
not sensitive enough to measure serum thiamin, but the concentration of total thiamin 
found in the serum of healthy subjects by this method compared well with 
concentrations reported using sensitive HPLC methods.116 Differences in 
methodology, and specifically the elevated readings by the microbiological method 
used may partly account for the smaller numbers of subjects with reduced serum 
thiamin levels in this study, compared with the study by Thornalley.2 In addition, for 
the assay method used in this study, the non parametric reference ranges for both 
serum and red cell thiamin were determined on 505 healthy individuals aged 18 to 90 
years in Australia prior to 1991.9 Mandatory enrichment of bread making flour in 
Australia since 1991 has increased the thiamin content of all breads to 0.45 mg/100 g 
(compared to 0.16 mg/100 g for white and 0.22 mg/100 g for wholemeal breads prior 
to thiamin fortification)10 with a concomitant increase in mean thiamin intake of 25% 
in men, and 20% in women in the Australian population.11 In those without diabetes 
and in the absence of excess alcohol, dietary intake of thiamin is the main 
determinant of thiamin status, therefore, it is reasonable to assume the reference 
levels used may now be too low. If this is so, it would not detract from the study 
results, merely increase the numbers of subjects with low serum and red cell thiamin 
levels. 
 
5.2 Modifiers of thiamin status  non dietary 
 
This study has shown reduced thiamin status in subjects with type 1 and type 2 
diabetes. Thiamin deficiency may result from inadequate dietary intake of the 
vitamin as well as from decreased absorption, defective transport, increased 
requirements, and enhanced losses14 and various modifiers may impinge on any of 
these processes.  
 
All known possible minor modifiers of thiamin status, age, duration of diabetes, 
BMI, physical activity, smoking status, diabetic control and urinary albumin 
excretion, were addressed in this study, with surprisingly little association found. 
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Age and duration of diabetes were found to have some initial positive association 
with thiamin status (age in type 2 subjects and duration in type 1 subjects) on 
preliminary testing but none on definitive testing with χ² and Pearsons correlation. 
There are conflicting reports in the literature as to the association of age and thiamin 
status, with biochemical evidence of thiamin deficiency being reported in both free 
living and institutionalized elderly people,72, 73 but other studies have indicated that 
age has no appreciable impact on thiamin status,70 so this was not unexpected. 
Surprisingly, there was no association found between urinary albumin excretion and 
thiamin status. Thornalley found evidence of increased renal clearance of thiamin in 
diabetes, with a 24-fold increase in type 1 and a 16-fold increase in type 2 diabetes 
and plasma thiamin levels negatively correlating with this2 and it is thought that the 
development of thiamin deficiency with increased renal clearance and albuminuria in 
diabetic rats may indicate abnormal renal handling of thiamin.8 Also poor diabetes 
control was not significantly associated with reduced thiamin status, even when 
addressing both HbA1c and episodes of hypoglycemia. None of the other minor 
modifiers investigated were shown to have an association with thiamin status in these 
subjects with diabetes. This was not inconsistent with the literature as all had 
conflicting reports on their effect on thiamin status, with none being consistently 
reported as modifiers. 
 




 The effect of the major modifier of thiamin status, excess alcohol consumption27,67,68 
was eliminated by the exclusion criteria of the study. Low levels of alcohol intake 
appear to have no appreciable affect on thiamin status.63  
 
5.3.2 Dietary intake 
    
As previously discussed, in those without diabetes, in the absence of excess alcohol,  
dietary thiamin intake is normally the major determinant of thiamin status.11,64,65,66 
Dietary intake was investigated in the present study at two levels, physiological (food 
intake) and pharmacological (thiamin supplementation). 
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Assessment of dietary thiamin 
A 24-h recall was used to assess dietary intake as this was a practical method of 
dietary assessment in a population such as this with varying literacy levels and 
sometimes poor English.90 The situation was conducive to taking a 24-h recall, with 
subjects available while waiting to see medical staff, few time constraints and a 
suitable interview room. Every effort was made to minimize systematic and random 
error to ensure accuracy of dietary data.   
 
Systematic error in the 24-h recall was reduced by using a standard interviewing  
technique, having the same interviewer, using a standardized method and form for 
food data entry and an appropriate database for nutrient analysis (AUSNUT99).87 In 
addition, subjects were given study information, signed a consent and undertook the 
24-h recall without prior warning, thus minimizing any subject-initiated changes to 
normal daily intake.86 
 
Random error in 24-h recall mainly originates in day-to-day variation in food intake 
which renders the data from a 24-h recall less representative of usual intake.87 This is 
reduced in estimating nutrients such as thiamin which are present in many foods, and 
therefore less likely to vary from day to day.94 Logically, thiamin is a suitable 
nutrient to assess intake by 24-h recall, as cereal products are a significant thiamin 
source and are generally eaten on a regular basis. Mandatory enrichment of bread-
making flour in Australia since 1991 has increased the thiamin content of white, 
mixed grain and wholemeal breads to 0.45 mg/100 g (compared to 0.16 mg/100 g for 
white and 0.22 mg/100 g for wholemeal breads prior to thiamin fortification)10 with a 
concomitant increase in thiamin intake in all sub-groups of the population.11 It is 
assumed this increase is due to thiamin fortification of bread-making flour.11 This 
would increase the proportionate contribution of cereals to daily thiamin intake, and 
thereby tend to reduce day to day variation in thiamin intake. Supporting this, the 
1995 National Nutrition survey showed breads and rolls contributed approximately 
20% of total thiamin intake in the Australian diet.82  A number of studies have 
demonstrated acceptable data for thiamin intake using 24-h recalls,90, 91, 100, 101 
although not all, with a study by Basiotis103 asserting 41 to 46 days of dietary data 
were required to enable thiamin intake to be accurately expressed as a yearly 
average.  
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Although direct evidence is lacking, it is thought that a relationship exists between 
thiamin requirement and energy metabolism arising from the role of thiamin as 
thiamin pyrophosphate in the metabolism of carbohydrate in glycolysis and in the 
citric acid cycle.40 Energy was assessed in order to be used in a secondary measure of 
thiamin adequacy, ie thiamin/1000 kJ. Similarly carbohydrate was assessed to 
determine contribution to energy intake, as where carbohydrate intakes are high 
(contributing greater than 55% of energy intake) there may be an increased need for 
thiamin.205 
 
Reproducibility of the 24-h recall in this study was assessed by repeat 24-h recalls on 
31 subjects (34.8% of the initial sample). There was no significant difference 
between those completing repeat recalls and the rest of the sample in basic 
demographics (age, gender, duration of diabetes, BMI, activity and smoking status).  
Reproducibility for total thiamin, carbohydrate and energy was assessed.  
 
Preliminary assessment using continuous variables showed good correlation between 
original and repeat values of thiamin, carbohydrate and energy (all significant at 0.01 
level). Correlation does not necessarily equate with agreement, however in this 
study, where we are examining the association of dietary intake of thiamin and serum 
and  red cell thiamin levels, a good correlation in thiamin intake between repeat 24-h 
recalls implies a ranking of thiamin intake between subjects that relates to their 
propensity to attain normal serum and red cell thiamin levels.  
 
Reproducibility was also assessed by means of a Bland-Altman plot for each 
nutrient, where differences are plotted against means and mean bias and limits of 
agreement calculated. The results of this for thiamin showed little variation in 
accuracy of assessment according to the quantity of thiamin assessed. Limits of 
agreement indicated that we can be confident that 95% of the time, the value of 
thiamin intake as assessed by repeat 24-h recalls will be within 0.6 mg of the original 
estimate across the range of measurement. This is approximately 50% of the RDI for 
thiamin (1.1 mg/day females, 1.2 mg/day males). As an RDI incorporates generous 
factors to accommodate variations in absorption and metabolism and exceeds the 
actual nutrient requirements of practically all healthy persons,55 a limit of agreement 
of 0.6 mg was considered acceptable. 
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 The limits of agreement for carbohydrate and energy intake (123.3 g and 4000 kJ 
respectively) although having little variation with varying carbohydrate and energy 
values, were wider, mooting less than ideal repeatability by 24-h recall for both these 
nutrients. Assessed carbohydrate and energy values, although useful were interpreted 
with some caution. 
 
Overall, the evidence was that the 24-h recalls gave acceptable accuracy of data for 
the purposes required in this study.  
Dietary thiamin  adequacy of intake 
a) Direct measure of thiamin intake 
Thiamin intake in this study had a non normal distribution thus median as well as 
mean values were calculated. Mean thiamin intake in this group was well above 
mean intakes in the general population, with median intakes considerably lower. 
Mean thiamin intakes recorded in the National Nutrition Survey in 1995 were 1.94 ± 
1.2 mg for adult males and 1.35 ± 0.76 mg for adult females.81 In both types of 
diabetes males had a higher median intake of thiamin than females, consistent with 
the trend noted in the 1995 National Nutrition Survey that males consumed larger 
quantities of vitamins and minerals than females82. With the exception of females 
with type 2 diabetes, median thiamin intake in all groups was ≥ than the RDI (1.2 mg 
M, 1.1 mg F). In females with type 2 diabetes 87.6% (78 subjects) had a median 
dietary thiamin intake above the RDI, which is still highly acceptable. Overall there 
was no evidence of low thiamin intake with respect to the reference population, 
consistent with a study by SV showing 98% of subjects with type 2 diabetes had an 
intake of thiamin above the RDI6 and a study in subjects with type 1 diabetes 
showing similar results.7 
b) Adequacy of thiamin intake measured by thiamin energy ratio 
Energy intake was normally distributed and mean energy intakes were less than the 
general population,  possibly due to dietary education emphasising low intakes of fat 
and sugars in this population, less than ideal repeatability of energy assessment by 
24-h recall or under-reporting. Under-reporting is well documented in assessments of 
energy intake by 24-h recall.206, 207 Mean energy intake was greater in those with type 
1 diabetes than those with type 2, which is not surprising as people with type 1 
diabetes were generally both younger and thinner than those with type 2 diabetes, 
and would generally have higher energy needs. In addition more type 2 subjects were 
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overweight, increasing the chance of their adherence to a weight loss regime. 
However, given that a larger proportion of this group were overweight and that 
under-reporting is more common among overweight and obese individuals, then this 
data may be less reliable.207 Information was not collected which would allow 
differentiation between under-reporters and those justifiably restricting energy intake 
for the purposes of weight reduction or improvement of control of diabetes. Males 
had higher mean energy intakes than females, consistent with the 1995 National 
Nutrition Survey results with mean daily energy intake of 11,050 ± 4,278 kJ for men 
compared to 7,481 ± 2,917 kJ for women.81 Thiamin intake per 1000 kJ was highly 
adequate in all subjects, and even in the context of possible understated values of 
energy, supports the thesis that almost all subjects had an adequate thiamin intake, as 
the lowest mean intake (for male subjects with type 2 diabetes) was 4+ times greater 
than 0.1 mg/1000 kJ (the previous recommended dietary intake).204  
c)  Adequacy of thiamin intake - increased need due to high carbohydrate 
Carbohydrate intake had a similar pattern with males in both groups having a higher 
mean carbohydrate than females, consistent with the National Nutrition Survey mean 
figures for the general population (males 301 ± 129 g,  females 211 ± 86.9 g).81  
Mean intakes were considerably lower in all subjects than the general population, 
possibly reflecting recommendations to decrease sugar intake in the diet for diabetes, 
but under-reporting can also be an issue when assessing carbohydrate intake.207 
Contribution of carbohydrate to total energy intake was interesting (all mean % 
values less than 46%), being lower than the sometimes recommendation of 50  60% 
for people with diabetes,208 but consistent with another study by SV.6 It was also 
considerably lower than the estimated 55% postulated to increase need for 
thiamin.205  
 
In summary, dietary intake of thiamin in these subjects was equal to and often greater 
than the reference population for adequacy of intake.  
 
5.4 Dietary thiamin intake and thiamin status 
 
The relationship between thiamin intake and thiamin status was addressed in two 
ways: 
a) Direct correlation between dietary variables and indices of thiamin status  
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In people without diabetes, blood thiamin levels correlate with dietary intake; a rise 
and fall in dietary thiamin intake in normal volunteers has been shown to be 
associated with a similar rise and fall in blood thiamin levels.209 In the 70 initial 
subjects who were not on thiamin supplementation there was no correlation between 
thiamin intake and serum or red cell thiamin. Scatterplots clearly show variables with  
little relationship to each other. In fact the two subjects with the lowest dietary 
thiamin intakes had red cell thiamin levels in the middle of the normal range and two 
subjects with dietary intakes almost double the RDI had red cell thiamin levels below 
the normal range. Similarly there was no correlation between serum or red cell 
thiamin and energy intake, carbohydrate intake or thiamin intake per 1000 kJ. The 
only comparable study is one by Saito in 1987, where prepared diets of 
predetermined quantities of thiamin, carbohydrate and energy were given to people 
with diabetes and blood thiamin levels measured. The length of time diets were given 
and methodology were not specified. This study found no significant correlation 
between blood thiamin levels and dietary thiamin, energy or carbohydrate; but did, 
however find a correlation between thiamin per 1000 kJ.209 A small study by SV in 
type 2 subjects showed red cell and serum thiamin did not correlate with any dietary 
variables.6  
b) Non parametric testing with categorical variables to address certain endpoints. 
This was definitive. On non parametric testing, dietary thiamin intake above the RDI 
was not significantly associated with having normal red cell or serum thiamin. Red 
cell thiamin correlated with serum thiamin in both groups and results did not differ 
significantly between those with type 1 and type 2 diabetes.  
 
5.5 Thiamin supplementation  
 
Thiamin supplements were taken by 19 out of 89 initial subjects (21.3%) This is 
lower usage than the general adult Australian population (43%).210 The highest 
median intake of vitamin supplements in the general population is by women over 
60, 210 thus it is rather surprising that type 2 subjects who had a mean age of 62 ± 
10.2 years had a rate of supplementation equivalent to the younger type 1 subjects. 
This population with type 2 diabetes is often highly medicated. A recent study in 
Melbourne on 50 subjects with type 2 diabetes showed they took 7 ± 2.97 different 
types of medications per day. The dose frequency included twice a day, three times a 
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day and four times a day.211 One can only surmise that in a population with such a 
high intake of medications, both for diabetes and related conditions, that extra 
medication is avoided. 
 
After extension of the study, supplemented subjects totalled 43. Of these, 25 were 
supplemented with thiamin nitrate and 18 with thiamin hydrochloride, forms of 
thiamin which are synthetic and not naturally present in food.23 Supplemented 
subjects had  a median total thiamin intake of 12.96 mg (plus dietary intake), well 
above the physiological range compared to median total thiamin intake of 1.1 mg in 
the unsupplemented group (equivalent to the RDI for women). The minimum total 
intake in the supplemented group was 4.01 mg of thiamin, almost four times the RDI, 
and  equivalent to the maximum intake in the unsupplemented group (4.44 mg). The 
maximum in the supplemented group  was 122.60 mg (plus dietary intake), over 100 
times the RDI.  
 
Therefore, although there was some overlap in total thiamin intake between the upper 
end of the unsupplemented group and the lower end of the supplemented group, total 
thiamin intake in the supplemented group was largely pharmacological, being in a 
different form and with a quantity generally in excess of the unsupplemented group.  
Thiamin supplementation and thiamin status 
After extension of the study, supplemented subjects totalled 43, and were compared 
with the 70 unsupplemented subjects for statistical testing. Statistical analysis with χ² 
and Pearsons correlation showed dietary thiamin intake above the RDI (n = 37) was 
not significantly associated with having normal red cell thiamin. Supplementation to 
total thiamin intake > 4 mg/day, however, was significantly associated with having 
normal red cell thiamin (p = 0.025), with 2.3% (n = 1) of subjects having low red cell 
thiamin. Similarly, supplementation to total thiamin intake > 4 mg/day was 
significantly associated with having a serum thiamin above the upper limit of the 
normal range (p < 0.001) (44.2%  of subjects, n = 17) compared to 0% of subjects in 
the unsupplemented group. This association was just as significant in those who had 
taken last supplement 24 hours previously (p < 0.001), with 45% of these subjects 
having elevated levels. Red cell thiamin correlated with serum thiamin (r = 0.463, p 
< 0.01; r = 0.426, p < 0.01) in both groups. Results did not differ significantly 
between those with type 1 and type 2 diabetes. 
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The subjects in the supplemented group were effectively thiamin loaded, and it is 
generally accepted that at higher concentrations, intestinal uptake of thiamin is 
predominately by diffusion23 rather than via the saturable carrier-mediated transport 
mechanism that predominates at physiological concentrations. This is in agreement 
with the very high levels of serum thiamin found in 44.2% of the supplemented 
group. Type of supplement (thiamin hydrochloride or thiamin nitrate) was not 
significantly associated with serum thiamin, which is concordant with animal studies 
which have found little difference between absorption of different  water-soluble 
supplemental thiamin salts, indicating that they have similar potency.49  There was a 
highly significant correlation (r = 0.59, p < 0.001) between total thiamin intake and 
serum thiamin in the supplemented group which was not present in the 
unsupplemented group. This is in agreement with literature reports that absorption of 
thiamin hydrochloride and thiamin nitrate is dose-dependent15  but conflicts with 
others which suggest  that humans have a rate-limited capacity to absorb water 
soluble thiamin supplements,48 that the proportion absorbed of water soluble 
supplements is very low,18 that at a supplementation level of  2.5  5 mg of thiamin, 
the majority is largely unabsorbed,18 and that daily absorption is usually limited to a 
maximum of 8-15 mg. The subject with the highest thiamin intake in this study 
(122.60 mg plus dietary intake) had a serum thiamin of 93.7 nmol/L (almost 60 
nmol/L above the upper limit of the normal range) which appears to mitigate against 
an upper level of absorption. It could be postulated that the levels have accumulated 
over time, but the presumption would be that a large proportion would be excreted. 
In addition, levels of serum thiamin remained high in 45% of subjects who ingested 
their last supplement ≥ 24 hours previously, which is surprising against the 
background of literature reports of rapid excretion of high dose thiamin44, 57 and 
increased levels of thiamin excretion in diabetes with excretion correlating inversely 
with plasma thiamin2 but in agreement with a literature report of only 2.5% of an oral 
dose of 50 mg of thiamin being recovered in the urine in non-diabetics.57  
 
This study showed no significant association between subjects having a 
physiologically adequate intake of thiamin and attaining normal levels of red cell 
thiamin. It has been suggested that mild thiamin deficiency in diabetes may induce 
increased expression of the thiamin transporters THTR1 and THTR2, to increase 
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tissue scavenging of thiamin, and a decrease in the expression of transporter RFC-1, 
to retain tissue thiamin pyrophosphate,8 however these mechanisms appeared 
insufficient to ensure adequate thiamin status in these unsupplemented subjects. 
Supplementation with thiamin, however, was significantly associated with normal 
red cell thiamin levels, which seems to indicate a difference in transport into the red 
cell.  In vitro studies of uptake of thiamin by erythrocytes in humans show it is 
probably transported by facilitated diffusion, by a low capacity carrier mechanism. 
Thus it is proposed that uptake has two different mechanisms, saturable and 
nonsaturable with the saturable mechanism dominating at physiological 
concentrations.54 Presumably the nonsaturable is dominating in the situation where 
thiamin supplementation has resulted in high serum thiamin levels, which may partly 
explain why supplemented subjects attained normal red cell levels of thiamin and 
unsupplemented subjects did not.  
 
Finally, the results of the present study thus discussed did not differ significantly 
between those with type 1 and type 2 diabetes which is possibly surprising as type 1 
and 2 diabetes generally have different origins, and are, to some extent different 
diseases, although, as has been discussed (see section 2.2.5), they may co-exist129 and 
also have some genetic overlap.128 Both types of diabetes, however, are diagnosed by 
a level of blood glucose which defines a group of people with a significantly 
increased risk of  premature mortality and microvascular and cardiovascular 
complications117 and both types of diabetes cause gross aberrations of carbohydrate 
metabolism, in which thiamin is involved. 
 
5.6  Summary 
 
Overall there is agreement in the literature that mild thiamin deficiency is prevalent 
in diabetes,2-4 characterized by reduced blood thiamin levels in those with diabetes 
compared to people without diabetes however the literature differs in the fractions of 
blood affected and the proposed causes of the deficiency. A recent review on the role 
of thiamin in diabetes8 stated that thiamin malnutrition is probably not caused by 
dietary deficiency of thiamin. There is, however a dearth of definitive studies 
addressing dietary intake and thiamin status,3 with the bulk of research concentrating 
on the potential role of thiamin and its derivatives in amelioration of some diabetic 
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complications.8 This study differs from others in having dietary intake data and has 
definitively shown in these subjects with diabetes that thiamin supplementation to 
total thiamin intake > 4 mg (approximately 3 times recommended intake) was 
significantly associated with having normal red cell thiamin levels but an adequate 
dietary intake of thiamin within the physiological range was not. Thiamin 
supplementation to total thiamin intake > 4 mg (approximately 3 times recommended 
intake) was also significantly associated with having a serum thiamin above the 
normal range, with 45% of subjects taking last supplement 24 hours previously 
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CHAPTER 6:   CONCLUSIONS AND RECOMMENDATIONS 
 
6.1  Conclusions 
 
The aim of this study was to clarify the relationship between red cell thiamin levels 
and dietary intake and diabetes control using direct dietary intake data and adequate 
numbers of subjects to provide sufficient power. To a certain extent this has been 
accomplished and the conclusions are: 
• The usual relationship between dietary thiamin and red cell thiamin does not 
exist in people with diabetes. 
• In diabetes an adequate intake of dietary thiamin does not ensure red cell 
thiamin level within the normal range. 
• Contrary to some reports in the literature serum thiamin does not appear to be 
affected to the same extent, but this may be an artefact of the thiamin assay 
used in this study. 
• Thiamin supplementation to total intake greater than 4 mg/day is significantly 
associated with a normal red cell thiamin level. 
• Thiamin supplementation to total intake greater than 4 mg/day is significantly 
associated with an elevated serum thiamin level. 
• Elevated serum thiamin levels persist  24 hours after thiamin supplementation 
in 45% of  subjects. 
• Poor diabetic control is not related to reduced blood thiamin levels. 
 
This study shows thiamin supplementation appears necessary to ensure acceptable 
thiamin status in diabetes. This raises questions as to actual thiamin requirements in 
diabetes and adds to evidence that thiamin deficiency in diabetes is not primarily due 
to dietary deficiency.  
 
6.2   Recommendations 
 
This was a cross-sectional study primarily looking at factors affecting thiamin status 
in diabetes. It has demonstrated that an adequate dietary intake is not sufficient to 
ensure adequate thiamin status in diabetes and that thiamin supplementation is 
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necessary. It would seem to be of immense benefit to follow this with an intervention 
study which could chart the changes in thiamin status with institution of thiamin 
supplementation, especially at different levels of supplementation. The present study 
showed the benefit of thiamin supplementation to a total thiamin intake of greater 
than 4 mg, however levels of supplementation varied greatly, and although the effect 
on red cell thiamin levels did not appear to vary, higher levels of supplementation 
were associated with much higher serum thiamin levels. It would be useful to 
quantify this relationship, while looking at the effect on red cell thiamin levels. Lipid 
soluble thiamin derivatives such as benfotiamin have greater bioavailability but are 
not easily obtained in Australia at present. In the longer term, a comparison study 
between this and water soluble thiamin supplements, as is normally used would be 
interesting. It would also be interesting to examine the effects of dietary intake to 4 
mg (perhaps via vegemite) to see if this ensured adequate thiamin status. 
 
A limitation of this study was the lack of data on thiamin excretion. It primarily 
looked at thiamin between the mouth and the red cell. An intervention study 
incorporating excretion would give more complete data. Thiamin excretion in 
diabetes as compared with normals has been addressed by Thornalley,2 however that 
study did not quantify or control for dietary thiamin intake. The link between thiamin 
and complications is firmly established, so some data on complications seems 
appropriate. Diabetic retinopathy is classified by stages, and would possibly be 
appropriate. 
 
Finally, the thorny question of thiamin assays. Many different standardized assays 
are currently used and accepted, but there is a general move towards universal use of 
high performance liquid chromatography,108 so this is the obvious method to be used 
in any future studies. 
 
6.3  Summary 
 
Therefore, the recommendations arising out of this study are for a follow up  
intervention study looking at the effect of different levels of thiamin 
supplementation,  possibly dietary intake to 4 mg, on serum and red cell thiamin and 
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thiamin excretion, with thiamin being assayed by high performance liquid 
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In Diabetes, Does The Amount Of Thiamine (Vitamin B1) Eaten, Or 
The Level Of Glucose In The Blood Affect How Much Thiamine Is 
Present In The Blood? 
 
Study Summary 
Thiamine (vitamin B1) is necessary for the body to use carbohydrate. 
Thiamine is present in some foods and when eaten is absorbed from the 
gut and enters the blood. People with diabetes tend to have lower levels 
of thiamine in their blood than people without diabetes. People usually 
only have low thiamine levels in their blood, if they do not eat enough 
thiamine. However this may not be the reason for low blood thiamine 
levels in diabetes, diabetes itself may be the cause.  
This study will measure the amount of thiamine eaten by a group of 
people with diabetes, and compare this to the level of thiamine in their 
blood. It will also compare a long term measure of diabetes control 
(haemoglobin A1c) to thiamine blood levels. 
This study has received ethical approval from Royal Perth Hospital 
Ethics Committee. 
 
Your Role In This Study 
If you consent to take part in the study, in formation will be obtained 
from you about the foods you have eaten over the last 24 hours. 
Information will be collected at this visit and no other appointment will 
be needed. This information will be compared with your blood levels of 
thiamine and HbA1c that are routinely tested with your other survey 
tests. There will be no other involvement by you, and no cost.  
You do not have to take part in this study if you do not want to. 
 
How The Information Will Be Handled. 
All identifying data will be deleted once your food intake and blood 
results have been compared. Your name will not appear on any 
document or publication. 
 
Further Information 
If you have any further questions, you can contact the dietitian in 
Diabetic Clinic on 92242162. 
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In Diabetes, Does The Amount Of Thiamine (Vitamin B1) Eaten, Or The Level Of 
Glucose In The Blood Affect How Much Thiamine Is Present In The Blood? 
 
Study Summary 
Thiamine (vitamin B1) is necessary for the body to use carbohydrate. Thiamine is present in 
some foods and when eaten is absorbed from the gut and enters the blood. People with 
diabetes tend to have lower levels of thiamine in their blood than people without diabetes. 
People usually only have low thiamine levels in their blood, if they do not eat enough 
thiamine. However this may not be the reason for low blood thiamine levels in diabetes, 
diabetes itself may be the cause.  
This study will measure the amount of thiamine eaten by a group of people with diabetes, and 
compare this to the level of thiamine in their blood. It will also compare a long term measure 
of diabetes control (haemoglobin A1c) to thiamine blood levels. 
This study has received ethical approval from Royal Perth Hospital Ethics Committee. 
 
Your Role In This Study 
If you consent to take part in the study, in formation will be obtained from you about the 
foods you have eaten over the last 24 hours. Information will be collected at this visit and no 
other appointment will be needed. This information will be compared with your blood levels 
of thiamine and HbA1c that are routinely tested with your other survey tests. There will be 
no other involvement by you, and no cost.  
You do not have to take part in this study if you do not want to. 
 
How The Information Will Be Handled. 
All identifying data will be deleted once your food intake and blood results have been 
compared. Your name will not appear on any document or publication. 
 
Further Information 
If you have any further questions, you can contact the dietitian in Diabetic Clinic on 
92242162. 
If you are happy to take part in the study you should now sign the CONSENT FORM.  
Thank you for considering participating in this study. 
 
 
CONSENT TO PARTICIPATION IN A STUDY TO ASSESS THE AFFECT 
OF THIAMINE INTAKE ON BLOOD THIAMINE LEVELS 
 
 
I,........................................................................ agree to participate in the above study.  I have 
read and understood the attached Information Sheet and I have retained a copy of the signed 
document.  I have been given the opportunity to ask questions about the study by the 
investigator.  I understand that I may withdraw from the study at any time without affecting 
any future medical treatment, or the treatment of the condition which is the subject of the 
trial. 
 




Signature of Investigator.............................................................   Date...........................  
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ID     
*DIABETES TYPE     
*GENDER     
*WEIGHT     
*HEIGHT     
BMI     




    
*? ON 
ANTIBIOTICS 
    
*NO. 
HYPOS/WEEK 
    
HbA1C     
SERUM THIAMIN     
RED CELL THIAMIN     
TOTAL THIAMIN      
CARBOHYDRATE     
ENERGY     



























    
Thiamin  24 
hour recall 
 
    
Thiamin - 
supplements 
    
Thiamin rich 
foods (av) 
    
Nutritional 
Supplements 
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Between 
Lunch &  
Dinner 














   
 
Thiamin Supplement _____________________________  amount _______________________ 
 
Nutritional Supplement____________________________ amount ________________________ 
 
Vegemite/Marmite________________________________ amount ________________________ 
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Diabetic Clinic                             Vitamin Supplement Survey 
 
Name______________                                         
                                                                                                 
  
Dear Survey Attendee,  
                                    I am doing a short survey of vitamin 
supplementation in people attending the Diabetic Survey. 
-Could you please fill in the three questions on the survey sheet 
below. 
-Could you return to the nurse when you attend the Diabetic 
Survey 
Many thanks for your participation.           
  
Sally Vindedzis  
Dietitian  
Endocrinology and Diabetes  






1. Do you normally take vitamin supplements?  
                               YES/NO    (Please circle one) 
2.  If yes, When did you last take your vitamin supplements?  
 On survey morning / The night before survey / The morning of the day 
before survey 
                                      (Please circle one). 
3. Which vitamin supplements do you take (see below) 
 
1st  Vitamin Supplement  
 





No of tablets taken per day_________________________________ 
 
 
2nd  Vitamin Supplement  
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No of tablets taken per day_________________________________ 
 
PLEASE ADD OTHER VITAMIN SUPPLEMENTS ON BACK OF SHEET IF 
NECESSARY. 
 
 
 
